

srgh
1958

SOCIETATEA ROMÂNĂ
DE GASTROENTEROLOGIE
ȘI HEPATOLOGIE



SOCIETATEA ROMÂNĂ DE
NEUROGASTROENTEROLOGIE
MEMBRI ÎN CALITATEA SOCIETĂȚII EUROPENE DE GASTROENTEROLOGIE



Clubul Român
pentru Boala Ciroze
și Colică Liverului



RSCP
Romanian Society of Gastroenterology



APPRE
APPRE

AL **45** -LEA

CONGRES NAȚIONAL DE GASTROENTEROLOGIE, HEPATOLOGIE ȘI ENDOSCOPIE DIGESTIVĂ

Poiana Brașov
17-20 iunie 2026



www.congres-gastro.ro



info@congres-gastro.ro





Dear Colleagues and Friends,

It is our great pleasure to welcome you to the **45th National Congress of Gastroenterology, Hepatology, and Digestive Endoscopy, taking place in Poiana Braşov, Romania, June 17–20, 2026.**

Recognized as the premier national scientific event in gastroenterology, it brings together leading experts, clinicians, researchers, and enthusiastic young gastroenterologists, creating a valuable platform for scientific exchange and professional interaction.

The National Congress will be a celebration of the multi-dimensional and dynamic character of our specialty and the perfect opportunity to share your passion, access cutting-edge content from top experts in the field, explore and contribute to advancements in the research and management of digestive diseases.

The 2026 Scientific Program will once again offer a comprehensive exploration of the landscape of digestive diseases. The first day will host the Pre-Congress ESPEN Life Long Learning (LLL) Course on “Nutrition in Gastrointestinal Diseases” (Module 12), followed by state-of-the-art lectures and invited presentations delivered by international and national leaders in the field.

The second day is traditionally reserved for Postgraduate Courses organized on several tracks (Gastrointestinal, Liver and Biliary Diseases, Digestive Endoscopy with hands-on training, and Abdominal Ultrasound POCUS). The following days will offer a wide range of topics organized in plenary sessions, keynote lectures, multidisciplinary dialogues, interactive challenging case presentations, academic debates, and video sessions.

A substantial part of the program will be dedicated to oral abstract presentations by early-career investigators, alongside expert-led poster tours, promoting meaningful discussions and fostering innovative ideas and practical solutions.

Finally, we want to express our gratitude to our esteemed faculty, organizers, and partners for their engagement in making this extraordinary event possible. We hope that, beyond sharing knowledge, the program will catalyze fruitful interactions, inspire scientific collaboration, and lay the foundation for enduring professional partnerships.

We look forward to welcoming you to **the National Congress of Gastroenterology, Hepatology, and Digestive Endoscopy** for what promises to be a stimulating and impactful event.

Cordially,

Liana Gheorghe

on behalf of the SRGH Scientific Board

Presidents of the Romanian Society of Gastroenterology and Hepatology

Tiberiu Spârchez
Octavian Fodor
Veniamin Runcan
Benedict Gheorghescu
Alexandru Oproiu
Dumitru Dumitrașcu

Carol Stanciu
Alexandru Oproiu
Monica Acalovschi
Mircea Diculescu
Ioan Sporea
Dan L. Dumitrașcu

Anca Trifan
Cristian Gheorghe
Marcel Tanțău
Liana Gheorghe



SOCIETATEA ROMÂNĂ DE
ENDOSCOPIE DIGESTIVĂ

Presidents of the Romanian Society of Digestive Endoscopy

Alexandru Oproiu
Carol Stanciu
Oliviu Pascu

Cristian Gheorghe
Marcel Tanțău
Adrian Săftoiu

Eugen Dumitru
Adrian Săftoiu
Bogdan Mateescu

Octavian Fodor and Tiberiu Spârchez Conferences through the years

CONFERENCE OCTAVIAN FODOR

2009	CLUJ-NAPOCA	Oliviu PASCU
2010	CRAIOVA	Adrian SĂFTOIU
2011	MAMAIA	Monica ACALOVSCHI
2012	TÂRGU MUREȘ	Mircea GRIGORESCU
2013	TIMIȘOARA	Vasile ANDREICA
2014	ORADEA	Daniela DOBRU
2015	IAȘI	Gheorghe BĂLAN
2016	CLUJ-NAPOCA	Dumitru DUMITRAȘCU
2017	BUCUREȘTI	Mircea GRIGORESCU
2018	CRAIOVA	Ioan SPOREA
2019	TIMIȘOARA	Andrada SEICEAN
2021	CONSTANȚA	Marcel TANȚĂU
2022	BUCUREȘTI	Vasile DRUG
2023	IAȘI	Roxana Lucia ȘIRLI
2024	CLUJ-NAPOCA	Carol STANCIU
2025	BUCUREȘTI	Simona BATAGA
2026	POIANA BRAȘOV	Cătălina MIHAL

CONFERENCE TIBERIU SPÂRCHEZ

2009	CLUJ-NAPOCA	Carol STANCIU
2010	CRAIOVA	Cristian GHEORGHE
2011	MAMAIA	Anca TRIFAN
2012	TÂRGU MUREȘ	Liana GHEORGHE
2013	TIMIȘOARA	Dan L. DUMITRAȘCU
2014	ORADEA	Cristina CIJEVSCHI PRELIPCEAN
2015	IAȘI	Zeno SPÂRCHEZ
2016	CLUJ-NAPOCA	Dan OLTEANU
2017	BUCUREȘTI	Alexandru OPROIU
2018	CRAIOVA	Ion ROGOVEANU
2019	TIMIȘOARA	Adrian GOLDIȘ
2021	CONSTANȚA	Eugen DUMITRU
2022	BUCUREȘTI	Mariana JINGA
2023	IAȘI	Carmen Bratievici FIERBINȚEANU
2024	CLUJ-NAPOCA	Dan GHEONEA
2025	BUCUREȘTI	Ion DINA
2026	POIANA BRAȘOV	Bogdan MATEESCU

SCIENTIFIC COMMITTEE

Honorary President SRGH Carol Stanciu

Monica Acalovschi	Eugen Dumitru	Ion Rogoveanu
Radu Badea	Carmen Fierbinţeanu Braticevici	Adrian Săftoiu
Vasile Balaban	Ovidiu Frăţilă	Larisa Săndulescu
Christian Banciu	Dan Gheonea	Andrada Seicean
Simona Bătaǵă	Cristian Gheorghe	Cătălin Sfarti
Gabriel Becheanu	Liana Gheorghe	Ana Maria Sîngeap
Ciprian Brisc	Irina Gîrleanu	Zeno Spârchez
Sergiu Cazacu	Adrian Goldiş	Ioan Sporea
Romeo Chira	Mircea Grigorescu	Carol Stanciu
Ştefania Bunduc Chirilov	Răzvan Iacob	Teodora Surdea-Bлага
Cristina Cijevschi Prelipcean	Speranţa Iacob	Vasile Şandru
Călin Cipăian	Mădălina Ilie	Roxana Şirli
Tudorel Ciurea	Mariana Jinga	Horia Ştefănescu
Mihai Ciocîrlan	Mircea Mănuc	Alina Tanţău
Camelia Cojocariu	Bogdan Mateescu	Marcel Tanţău
Gabriel Constantinescu	Cătălina Mihai	Eugen Tcaciuc
Dana Crişan	Ofelia Moşteanu	Elena Toader
Mirela Dănilă	Lidia Munteanu	Cristina Tocia
Mircea Diculescu	Lucian Negreanu	Ion Tofolean
Ion Dina	Olga Oraşan	Anca Trifan
Daniela Dobru	Corina Pop	Theodor Voiosu
Vasile Drug	Alina Popescu	Andrei Voiosu
Dan L. Dumitraşcu	Bogdan Procopeţ	Roxana Zaharie
Dumitru Dumitraşcu	Mihai Rîmbaş	

INTERNATIONAL FACULTY

Elina Berliba	Nara Nairi
Gianluca Esposito	Angela Peltec
John Gásdal Karstensen	Carlo Senore
Thomas Horbach	Martina Muller-Schilling
Istvan Hritz	Molnar Tamas
Uri Kopylov	Eugen Tcaciuc
Remy Meier	Adela Turcan



REGISTRATION AND INFORMATION OFFICE

The Congressional Registration and Information Office will be located at the Entrance K2 Alpin - Events Center Poiana Ursului Street, 500001 Braşov



OFFICIAL LANGUAGE OF THE EVENT

Presentations will be given in Romanian SLIDES and POSTERS in English language.



21 EMC



CERTIFICATE OF PARTICIPATION

Each participant will receive a participation certificate after completing the feedback about the event, which please leave at the secretariat by June 20th. The certificate will be received by e-mail by July 30th. Please leave all the necessary information at the secretariat.



Access to the conference room will be based on the badge


Access to the dinner will be based on the vouchers




The speaker area is reserved exclusively for speakers. This area is designed to allow speakers to prepare for their presentations.



Public transport: bus no. 20 on the Braşov – Poiana Braşov route, departing from Livada Poştei Braşov every 20 minutes, until K2 Alpin - Events Center Poiana Ursului Street, 500001 Braşov



Conference Room
Atlas



Conference Room
Altai





Conference Room
Ural



Conference Room
Pamir

WEDNESDAY, JUNE 17TH 2026

PROGRAM AT A GLANCE

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
11:00-15:00	<p>ESPEN Course: Nutritional Support in Gastrointestinal Diseases Speakers: Remy Meier, Raluca Ungureanu MODULE 12 TOPIC: NUTRITION IN GI DISSEASES 13:00-13:30 Coffee break 13:30-15:00 Clinical cases and test all panel</p>		<p>TRAVELING ENDOSCOPY PROGRAM: QUALITY IN ENDOSCOPY – SRED/ESGE PARTNERSHIP COURSE DIRECTORS – Bogdan Mateescu, Lucian Negreanu</p>		
15:00-16:10	<p>AstraZeneca Symposium (20 min): Ewopharma Symposium (30 min) Terapia Symposium (20 min)</p>				
16:10-16:25	Coffee break ☕				
16:25-17:00	Opening Ceremony				
17:00-17:25	<p>State of the Art Lecture Carlo Senore The evolving landscape of colorectal cancer screening in Europe</p>				
17:25-17:50	<p>State of the Art Lecture Martina Muller-Schilling Screening for chronic liver disease: standard liver tests, prognostic scores and fibrosis assessment</p>				
17:50-18:00	<p>Book launch: Looking forward, thinking backwards Academician Profesor Dr. Carol Stanciu</p>				
18:00-18:20	<p>Octavian Fodor Conference Breaking the ceiling in Inflammatory Bowel Diseases: between the starry heavens and the moral law Cătălina Mihai</p>				
18:20-18:40	<p>Tiberiu Spârchez Conference Reshaping the Future: RSDE from annual congress to continuous education, quality and professional community Bogdan Mateescu</p>				
18:40	 Welcome cocktail – Forest Restaurant the Alpin Hotel - ACCESS ONLY WITH VOUCHER! 				



THURSDAY JUNE 18TH 2026

PROGRAM AT A GLANCE

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
8:00-9:30	Postgraduate Course GASTROENTEROLOGY Cristian Gheorghe, Dan Ghonea, Mircea Diculescu Session 1 UPPER GASTROINTESTINAL TRACT - Anca Dimitriu - Cătălin Sfarti - Adrian Goldiş - Cristina Cijevschi	Postgraduate Course HEPATOLOGY Liana Gheorghe, Anca Trifan, Corina Pop Session 1 ADVANCES IN THE MANAGEMENT OF CIRRHOSIS COMPLICATIONS - Bogdan Procopeţ, - Dana Nicoară Farcau - Ion Rogoveanu - Alina Popescu - Ioan Sporea	Postgraduate Course DIGESTIVE ENDOSCOPY Bogdan Mateescu, Lucian Negrean Session PRIMER FOR THE BEGINNER ENDOSCOPIST - Vasile Drug - Cristina Pojoga - Cristian Gheorghe - Bogdan Mateescu	Postgraduate Course ABDOMINAL ULTRASOUND POCUS Radu Badea, Ioan Sporea, Alina Popescu, Ioan Tofolean, Zeno Spârchez Session 1 PRINCIPLES. BILIARY DISORDERS - Radu Badea - Ioan Tofolean	Nurse Training Course Session 1
9:30-9:45	Coffee break ☕				
9:45-11:15	Session 2 SMALL BOWEL - Alina Tanţău - Ana-Maria Sângeap - Mircea Diculescu - Lucian Negreanu	Session 2 ALD, MetALD & PROGRESSIVE MASLD: WHAT'S NEW IN SCREENING AND MANAGEMENT - Liana Gheorghe - Roxana Şirli - Dana Crişan - Horia Ştefănescu	Session ENDOSCOPY IN IBD - Cristian Gheorghe - Cristian Tiereanu - Marcel Tanţău - Monica State Expert insights: – using endoscopy scores in real life - Uri Kopylov	Session 2 LIVER - Ioan Sporea - Ioan Sporea - Mirela Dănilă - Ciprian Brisc	Session 2
11:15-12:00	Zentiva Symposium (40')	Dr.Reddy's Symposium (30') Opella Symposium (15')		Biocodex Symposium (30') Synevo Symposium (15')	
12:00-12:15	Coffee break ☕				
12:15-13:30	Gilead Symposium (60') Johnson & Johnson Symposium (15')	Lilly Obesity Symposium (45') Opella Symposium (15') Nutricia Symposium (15')		Dr.Max Symposium (30') Sandoz Symposium (30')	
13:30-14:20	Lunch break 🍴				



THURSDAY JUNE 18TH 2026

PROGRAM AT A GLANCE

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
14:20-15:50	Session 3 PANCREATO-BILIARY DISEASES - Vasile Drug - Andrada Seicean - Vasile Sandru - Mariana Jinga Discussions	Session 3 VIRAL HEPATITIS: STILL HERE? - Liana Gheorghe - Mihaela Ghioca - Corina Pop - Sorina Diaconu - Anca Streinu-Cercel - Anca Trifan - Laura Huiban	Session EMERGENCIES IN DI- GESTIVE ENDOSCOPY - Bogdan Miutescu - Voicu Mercea - Teodor Voiosu - Marcel Tantău	Session 3 PANCREAS - Larisa Săndulescu - Zeno Spârchez - Adrian Săftoiu	Session 3
15:50-16:55	AbbVie Symposium (60')	Medochemie Symposium (30') Salveo Symposium (30')		Ferring Symposium (30') Lilly Symposium (35')	
16:55-17:10	Coffee break ☕				
17:10-17:30	Rising Star Conference TBA				
17:30-19:00	Session 4 COLORECTAL DISEASES - Dan Dumitraşcu - Cristian Gheorghe - Eugen Dumitru - Dan Gheonea	Session 4 HCC RISK, SURVEILLANCE AND MANAGEMENT - Larisa Săndulescu - Răzvan Cerban - Mugur Grasu - Zeno Spârchez - Speranța Iacob	Session MANAGING PATIENTS WITH OBESITY - Thomas Horbach - Bogdan Mateescu - Vasile Sandru - Alina Spinean	Session 4 GASTROINTESTINAL TRACT - Anda Leş - Roxana Şirli - Alina Popescu	Gastroenterology Brainstorm Arena
19:00					



FRIDAY JUNE 19TH 2026

PROGRAM AT A GLANCE

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
8:00-9:30	THE ROLE OF MULTI-DISCIPLINARY TEAM IN GASTROENTEROLOGY - Liana Gheorghe - Alin Nicolescu - Mihai Ciocirlan - Florin Grama - Cristian Gheorghe - Oana Stănciulea	HOT TOPICS IN HEPATOLOGY - Ciprian Brisc - Zeno Spârchez - Bogdan Procopeț - Robert Năstasă, - Camelia Cojocariu - Gheorghe Bălan - Anca Trifan -Iulia Minciună	VIDEOMARATHON	Acute and chronic pancreatitis - Mihai Eftimie - Cătălin Sfarmi - Adrian Săftoiu - Vasile Daniel Balaban - Ioan Cristian Nedelciu OP	Intestinal ultrasound - Roxana Saizu - Ioan Tofolean - Anda Leș
9:30-10:30	Opella Symposium (15') Ipsen Symposium (45')	AbbVie Symposium (60')		Dicofarm Symposium (20') Terapia Symposium (30')	
10:30-10:45	Coffee break ☕				
10:45-12:15	ULCERATIVE COLITIS OF OUR DAYS: ADVANCEMENTS IN DIAGNOSIS AND MANAGEMENT - Mircea Dicuilescu - Lucian Negreanu - Adrian Goldiș - Cristian Gheorghe - Oana Stănciulea OP	AUTOIMMUNE & CHOLESTATIC LIVER DISEASES: NEW TOOLS, NEW TREATMENTS, AND SYMPTOMS MANAGEMENT - Irina Girleanu - Mihaela Ghioca - Andrada Seicean - Liana Gheorghe - Carmen Ester - Speranța Iacob	COMPLICATIONS IN ENDOSCOPY - Gabriel Constantinescu - Alexandra Butnaru - Olteanu Delia - Mateescu Bogdan - Mihai Alexandru - Smeu Mare - Alexandra Dumitrescu	DIGESTIVE DISEASE AND AGEING – WHERE ARE WE GOING? - Cristina Cijevschi - Gabriel Prada - Iolanda Popa - Otilia Nedelciuc - Mihaela Dranga - Cătălina Raluca Nuta - Ovidiu Lucian Băjenaru Discussions	GASTRIC CANCER UP TO DATE - Simona Bataga - Dan Dumitrașcu - Mihai Ciocirlan - Marius Ciorbă
12:15-13:50	Lilly Symposium (45') Innergy Symposium (20') Novo Nordisk Symposium (30')	Krka Symposium (30') Opella Symposium (15') Mayoly Symposium (30') Sobi Symposium (15')		Secom Symposium (15') Nestle Symposium (20') Alfasigma Symposium (45')	
13:50-14:45	Lunch Break 🍽️	RSDE General Assembly			
14:45-16:15	CROHN'S DISEASE: KEY CONCEPTS IN DIAGNOSIS, MANAGEMENT AND MONITORING IN 2026 - Dan Gheonea - Liana Gheorghe - Anca Trifan - Horia Minea - Alina Tanțău - Florin Grama OP	MASLD – THE PANDEMIC OF OUR TIMES: FROM EPIDEMIOLOGY TO THERAPY - Dana Crișan - Larisa Săndulescu - Alina Popescu - Ioan Sporea - Carmen Fierbințeanu Braticevici OP	BASIC ENDOSCOPY TECHNIQUES IN REAL LIFE - Ștefan Chiriac - Cristian Tefas - Voicu Mercea - Ruxandra Mare - Ioan Cristian Nedelcu - Andrei Voiosu OP	HOT TOPICS IN GASTROENTEROLOGY - Giorgiana Gilcă - Cătălina Mihai - Eugen Dumitru - Anca Dimitru - Petruța Filip OP	ORAL PRESENTATION 2
16:15-17:45	THE ROLE OF PATHOLOGIC REPORT IN GASTROENTEROLOGY: WHAT EVERY GASTROENTEROLOGIST SHOULD KNOW - Liana Gheorghe - Gabriel Becheanu - Cristina Tocia - Cristina Gheorghe - Mona Dumbrava - Bogdan Cotruță	CIRRHOSIS AND COMPLICATIONS - Ion Rogoveanu - Ana-Maria Singeap - Simona Juncu - Liana Gheorghe - Mihaela Ghioca - Roxana Șirli OP	ETHICS AND MALPRAXIS IN DIGESTIVE ENDOSCOPY - prosecutor Simona Anghel - lawyer Cătălina Bordianu - Horia-Roman Patapievici Discussions	HEREDITARY COLORECTAL CANCER SYNDROMES - Daniela Dobru - Răzvan Iacob - Dragoș Cretoiu - Elena Toader - Gabriel Becheanu OP	NONINVASIVE TESTS IN CHRONIC LIVER DISEASES - Alina Popescu - Ioan Sporea - Bogdan Procopeț
17:45-18:00	Coffee break ☕				

FRIDAY JUNE 19TH 2026

PROGRAM AT A GLANCE

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
18.00-19:30	EFFECTIVE COLORECTAL CANCER SCREENING : HOW TO INCREASE THE ADHERENCE ? - <i>Mircea Mănuç</i> - <i>Cristian Gheorghe</i> - <i>Bogdan Cotrujă</i> - <i>Carlo Senore</i> Discussions	SPECIAL TOPICS IN HEPATOLOGY - <i>Adriana Cavasi</i> - <i>Corina Pop</i> - <i>Tudor Mocan</i> - <i>Olga Orăşan</i> OP		PSIHOASTROENTER- OLOGY - <i>Simona Grad</i> - <i>Laurențiu Nedelcu</i> - <i>Liudmila Tofan-Scutaru</i> - <i>Abdulrahman Ismaiel</i> - <i>Ovidiu Frățilă</i> - <i>Cristina Sabo</i>	JOINT SESSION 1 - <i>Eugen Teaciuç</i> - <i>Svetlana Turcan,</i> - <i>Alina Jucov</i> - <i>Abdulrahman Ismaiel</i> OP
19:30-20:15	SRGH GENERAL ASSEMBLY				
20:15	Dinner  Poiana Braşov Recreation Center ACCESS ONLY WITH VOUCHER! 				



SATURDAY JUNE 20TH 2026



PROGRAM AT A GLANCE

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
8:30-10:00	RECTAL CANCER - Cristian Gheorghie - Iulia Grecu - Adina Croitoru - Vasile Binţinţan - Victor Tomulescu	LIVER TRANSPLANT & SURGERY FOR CIRRHOTIC PATIENTS - Horia Ştefănescu - Ana Maria Sîngeap - Irina Gîrleanu - Cristina Muzica - Speranţa Iacob	HOW TO APPLY ADVANCED ENDOSCOPY TECHNIQUES IN REAL LIFE - Ioan Cristian Nedelcu - Mihai Ciocîrlan - Mădălina Ilie - Gheorghe Bălan - Andrada Seicean - Teodor Voiosu - Voicu Rednic - Adrian Săftoiu - D. Burtea - Mircea Mănuc OP	NEUROGASTROENTEROLOGY - Teodora Surdea-Blaga - Flaviu Rusu, Anca Dimitriu, - Ion Băncilă - Diana-Elena Floria, - Mahmoud Obeidat, Balint Eross, Oana-Bogdana Barboi, Radu Vulpoi, Vadim Roşca, Vasile Liviu Drug - Vadim Roşca, Asbjorn Mohr Drewes, Esben Mark, Liao Donghua, Camelia Cojocariu, Oana Barboi, Radu Vulpoi, Roxana Rusu, Liliana Gheorghe, Diana Floria, Constantin Simiras, Vasile Drug and Aalborg	JOINT SESSION 1 (R. Moldova) - Adela Turcan - Elina Berliba - Angela Peltec - Cristina Muzica - Anca Trifan
10:00-11:00	AstraZeneca Symposium (40') AstraZeneca Symposium (20')	Dr.Reddy's Symposium (20') Dr.Reddy's Symposium (20')			
11:00-11:15	Coffee break ☕				
11:15-12:45	PANCREATIC SOLID LESIONS - Andrada Seicean - Cristian Gheorghie - Cătălina Vlăduţ - Mihai Ciocîrlan - Sergiu Cazacu OP	PREDICTION IN HEPATOLOGY - Roxana Şirli - Larisa Săndulescu - Ioan Sporea - Corina Radu - Dana Matei	BEST ABSTRACTS - Delia Olteanu, - Radu Bogdan Mateescu - Sorina Telescu OP	What's NEW in NETS ? - Cătălina Poiana - Mircea Diculescu - Adina Croitoru Clinical case report 1 Clinical case report 2 (Gastroenterology) Clinical case report 3 (Oncology)	ORAL PRESENTATION 2 Chair: Ion Dina, Simona Bataga
12:45-13:00	Closing Session and Award Ceremony 🏆				



WEDNESDAY, JUNE 17TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
11:00-15:00	<p>ESPEN Course: Nutritional Support in Gastrointestinal Diseases Speakers: Remy Meier, Raluca Ungureanu</p> <p>MODULE 12 TOPIC: NUTRITION IN GI DISEASES 11:00-11:30 Compromised gut Remy Meier 11:30-12:00 Challenges in treating the patient with short bowel Raluca Ungureanu 12:00-12:30 Nutrition and gastrointestinal fistulas Raluca Ungureanu 12:30-13:00 Nutrition in inflammatory bowel disease -IBD Remy Meier 13:00-13:30 Coffee break 13:30-15:00 Clinical cases and test all panel</p>		<p>TRAVELING ENDOSCOPY PROGRAM: QUALITY IN ENDOSCOPY – SRED/ESGE PARTNERSHIP</p> <p>COURSE DIRECTORS - Bogdan Mateescu, Lucian Negreanu</p>		
15:00-16:10	<p>AstraZeneca Symposium (20 min): Challenges in the diagnosis and management of patients with LAL-D - <i>Liana Gheorghe</i></p> <p>Ewopharma Symposium (30 min) - Hypophosphataemia: A key factor influencing the response to intravenous iron in IBD patient - <i>Cătălina Poiana, Lucian Negreanu</i></p> <p>Terapia Symposium (20 min) MASLD and hepatoprotective therapy: current insights and clinical applications - <i>Speranța Iacob</i></p>				
16:10-16:25	Coffee break ☕				
16:25-17:00	Opening Ceremony				
17:00-17:25	<p>State of the Art Lecture Carlo Senore The evolving landscape of colorectal cancer screening in Europe</p>				
17:25-17:50	<p>State of the Art Lecture Martina Muller-Schilling Screening for chronic liver disease: Standard liver tests, prognostic scores and fibrosis assessment</p>				
17:50-18:00	<p>Book launch: Looking forward, thinking backwards Academician Profesor Dr. Carol Stanciu</p>				
18:00-18:20	<p>Octavian Fodor Conference Breaking the ceiling in inflammatory bowel diseases: between the starry heavens and the moral law Cătălina Mihai</p>				
18:20-18:40	<p>Tiberiu Spârchez Conference Reshaping the future: RSDE from annual congress to continuous education, quality and professional community Bogdan Mateescu</p>				
18:40	 Welcome cocktail – Forest Restaurant the Alpin Hotel - ACCESS ONLY WITH VOUCHER! 				

THURSDAY JUNE 18TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
8:00-9:30	<p>Postgraduate Course GASTROENTEROLOGY</p> <p>Cristian Gheorghe, Dan Gheonea, Mircea Diculescu</p> <p>CLINICAL PRACTICE IN GASTROENTEROLOGY: WHAT EVERY GASTROENTEROLOGIST SHOULD KNOW?</p> <p>Session 1 UPPER GASTROINTESTINAL TRACT</p> <p>Chair: Cristina Cijevschi, Adrian Goldiș, Eugen Dumitru</p> <ol style="list-style-type: none"> Eosinophilic esophagitis management: clinical and histological remission - Anca Dimitriu Barrett update: What is really important in 2026? - Cătălin Sfarti Preventive gastric cancer: gastric intestinal metaplasia and dysplasia management - Adrian Goldiș The risk of adenocarcinoma after Helicobacter pylori treatment - Cristina Cijevschi <p>Discussions</p>	<p>Postgraduate Course HEPATOLOGY</p> <p>Liana Gheorghe, Anca Trifan, Corina Pop</p> <p>ADVANCING HEPATOLOGY TO REDUCE THE LIVER DISEASE BURDEN</p> <p>Session 1 ADVANCES IN THE MANAGEMENT OF CIRRHOSIS COMPLICATIONS</p> <p>Chair: Ion Rogoveanu, Bogdan Procopet, Ioan Sporea</p> <ol style="list-style-type: none"> Transjugular intrahepatic porto-systemic shunt (TIPSS): Expanding indications and risk stratification - Bogdan Procopet, Oana Nicoară Farcau Recent developments in the management of refractory and recurrent ascites and hydrothorax - Ion Rogoveanu A personalized approach to the management of hepatic encephalopathy - Alina Popescu Role of non-invasive fibrosis tests and their longitudinal changes in monitoring and prediction of liver-related events - Ioan Sporea 	<p>Postgraduate Course DIGESTIVE ENDOSCOPY</p> <p>Bogdan Mateescu, Lucian Negreanu</p> <p>Session PRIMER FOR THE BEGINNER ENDOSCOPIST</p> <p>Chair: Adrian Săftoiu, Andrada Seicean, Cristian Gheorghe</p> <ol style="list-style-type: none"> Optimizing bowel preparation - Vasile Drug Optical diagnosis of colonic polyps - Cristina Pojoga Common resection techniques for colorectal polyps - Cristian Gheorghe Proctology for the gastroenterologist - Bogdan Mateescu Quiz time – test your knowledge! 	<p>Postgraduate Course ABDOMINAL ULTRASOUND POCUS</p> <p>Radu Badea, Ioan Sporea, Alina Popescu, Ioan Tofolean, Zeno Spârchez</p> <p>METHODS, TECHNIQUES, AND APPLICATIONS IN THE ULTRASONOGRAPHIC ASSESSMENT OF THE DIGESTIVE ORGANS</p> <p>Session 1 PRINCIPLES. BILIARY DISORDERS</p> <p>Chair: Radu Badea, Ioan Sporea, Alina Popescu</p> <ol style="list-style-type: none"> Ultrasonographic technologies used in gastroenterology. Principles, modes, advantages, and limitations - Radu Badea Biliary disorders: bile ducts and gallbladder. Indications. Added diagnostic value - Ioan Tofolean 	<p>Nurse Training Course</p> <p>Session 1</p> <p>Colorectal cancer screening – The role of nurses in the context of implementing a National Program</p> <p>Epidemiology of colorectal cancer – Identification of the target group</p> <p>- As. med. Aura Georgescu - As. med. Mihaela Batog</p> <p>The importance of patient education and preparation within the colorectal cancer screening program</p> <p>- As. med. Adina Mladin - As. med. Adela Nedelcu</p> <p>FIT test for colorectal cancer</p> <p>- As. med. Cosmin Știucă - As. med. Florentina Tutuianu</p> <p>Beyond endoscopy: The role of communication and the medical context</p> <p>- As. med. Giorgiana Chesnoiu - As. med. Daniela Burtea</p> <p>Polypectomy: From individual performance to team-work</p> <p>- As. med. Dana Burtea</p> <p>Testing for SIBO: indications and limitations. From personal experience to guideline recommendations</p> <p>- As. med. Liliana David, - As. med. Castalia Maier, - As. med. Geta Pop</p>
9:30-9:45	Coffee break ☕				



THURSDAY JUNE 18TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
9:45-11:15	<p>Session 2 SMALL BOWEL</p> <p>Chair: <i>Mircea Diculescu, Lucian Negreanu, Ana Maria Sângeap</i></p> <ol style="list-style-type: none"> Diet interventions for gut diseases - <i>Alina Tanţău</i> Approach to obscure GI bleeding - <i>Ana-Maria Sângeap</i> Update in diagnosis and treatment in short bowel disease - <i>Mircea Diculescu</i> Diagnosis and management of celiac disease - <i>Lucian Negreanu</i> 	<p>Session 2 ALD, MetALD & PROGRESSIVE MASLD: WHAT'S NEW IN SCREENING AND MANAGEMENT</p> <p>Chair: <i>Liana Gheorghe, Roxana Şirli, Dana Crişan</i></p> <ol style="list-style-type: none"> Challenges in diagnosis, risk stratification and management of MetALD - <i>Liana Gheorghe</i> A multidisciplinary approach to liver care, addiction and nutrition in ALD patients - <i>Roxana Şirli</i> Current treatment and future perspective in MASH - <i>Dana Crişan</i> MASLD and liver cancer: challenges in diagnosis, management and outcome - <i>Horia Ştefănescu</i> 	<p>Session ENDOSCOPY IN IBD</p> <p>Chair: <i>Cristian Gheorghe, Marcel Tanţău, Uri Kopylov</i></p> <ol style="list-style-type: none"> Severe endoscopic lesions in IBD - <i>Cristian Gheorghe</i> Mucosal healing in IBD – hitting a moving target - <i>Cristian Tiereanu</i> Endoscopic neoplastic lesions in IBD - <i>Marcel Tanţău</i> Case-based discussion - <i>Monica State</i> Expert insights: using endoscopy scores in real life - <i>Uri Kopylov</i> 	<p>Session 2 LIVER</p> <p>Chair: <i>Larisa Săndulescu, Mirela Dănilă, Ioan Tofolean</i></p> <ol style="list-style-type: none"> Why do we need ultrasound for gastroenterologists/hepatologists? - <i>Ioan Sporea</i> Ultrasound evaluation of diffuse liver diseases - <i>Ioan Sporea</i> Ultrasound assessment of benign liver tumors - <i>Mirela Dănilă</i> Ultrasound assessment of malignant liver tumors. - <i>Ciprian Brisc</i> 	<p>Session 2 The Nurse – A key factor in meeting quality indicators in colonoscopy - <i>As. med. Mihaela Ilie-Calita</i></p> <p>Optimal equipment conditions for a digestive endoscopy laboratory - <i>As. med. Gyongui Ghereg</i></p> <p>Stoma – Care and patient education - <i>As. med. Georgeta Păsărin</i></p> <p>Percutaneous gastrostomy - <i>As. med. Costin Mangaru</i></p> <p>Endoscopic gastroplasty - <i>As. med. Carmen Pop</i></p>
11:15-12:00	<p>Zentiva Symposium (40') Gut dysbiosis and overlap syndrome: two sides of the same gastrointestinal coin? - <i>Liana Gheorghe, Cristian Gheorghe</i></p>	<p>Dr.Reddy's Symposium (30') Management of gastroduodenal disorders with rabeprazole – current clinical perspectives - <i>Dan Gheonea</i></p> <p>Opella Symposium (15') The role of Bacillus Clausii spores in supporting intestinal flora - <i>Călin Cipăian</i></p>		<p>Biocodex Symposium (30') When do we choose an approved probiotic drug? The role of S. boulardii CNCM I-745 in the prevention and treatment of antibiotic-associated diarrhea in light of new clinical evidence on H. pylori eradication - <i>Lucian Negreanu</i></p> <p>Synevo Symposium (15') How to explore the dark side of the moon, in colorectal cancer investigation. - <i>Mircea Diculescu</i></p>	
12:00-12:15	Coffee break ☕				
12:15-13:30	<p>Gilead Symposium (60') Gilead Sciences – innovation and perspectives in the treatment of viral hepatitis</p> <ol style="list-style-type: none"> Viral hepatitis B, C and Delta – severity, impact and clinical consequences - <i>Corina Pop</i> HEPCLUDEX® (bulevirtide) – long-term confirmed efficacy and safety - <i>Liana Gheorghe</i> HEPCLUDEX® (bulevirtide) – from viral response to patients' quality of life - <i>Anca Trifan</i> <p>Johnson & Johnson Symposium (15') Next horizon in IBD care – new perspectives on IL23 - <i>Dan Gheonea</i></p>	<p>Lilly Obesity Symposium (45') Mounjaro – New perspectives in the treatment of obesity from the gastroenterologist's point of view - <i>Dan Gheonea, Bogdan Mateescu, Lucian Negreanu</i></p> <p>Opella Symposium (15') Management of constipation – a common disorder of the gastrointestinal tract - <i>Daciana Dascălu</i></p> <p>Nutricia Symposium (15') Translating clinical nutrition into patient care: impact and therapeutic approaches - <i>Bogdan Mateescu</i></p>		<p>Dr.Max Symposium (30') Gastric acid suppression and gut microbiota: clinical implications - <i>Cristian Gheorghe, Mircea Diculescu</i></p> <p>Sandoz Symposium (30') Addressing unmet needs in fistulizing Crohn's disease: pyzchiva and advanced Insights in IBD Care - <i>Cristian Gheorghe</i></p> <p>The role of the microbiota in celiac disease, inflammatory bowel diseases, and IBS - <i>Lucian Negreanu</i></p>	
13:30-14:20	Lunch break 🍽️				

THURSDAY JUNE 18TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
14:20-15:50	<p>Session 3 PANCREATO-BILIARY DISEASES Chair: <i>Andrada Seicean, Mariana Jinga, Lucian Negreanu</i></p> <p>1. Approach to obstructive jaundice: is it benign or malignant? - <i>Vasile Drug</i></p> <p>2. Acute pancreatitis: predictors of severity and principles of treatment - <i>Andrada Seicean</i></p> <p>3. Urgent and emergency ERCP in acute biliary pancreatitis - <i>Vasile Sandru</i></p> <p>4. Risk assessment of presumed pancreatic mucinous cyst - <i>Mariana Jinga</i> Discussions</p>	<p>Session 3 VIRAL HEPATITIS: STILL HERE? Chair: <i>Anca Trifan, Corina Pop, Sorina Diaconu</i></p> <p>1. HDV therapy: standard of care and emerging therapies - <i>Liana Gheorghe, Mihaela Ghioca</i></p> <p>2. Current antiviral therapy for hepatitis B: What's new in the EASL Guideline 2025 - <i>Corina Pop, Sorina Diaconu</i></p> <p>3. Next generation of HBV therapeutics: from functional cure to disease clearance - <i>Anca Streinu-Cercel</i></p> <p>4. MASLD and viral hepatitis: key insights for clinical practice - <i>Anca Trifan, Laura Huiban</i></p>	<p>Session EMERGENCIES IN DIGESTIVE ENDOSCOPY Chair: <i>Eugen Dumitru, Gabriel Constantinescu, Marcel Tanţău</i></p> <p>1. Endoscopic management of CBD stones - <i>Bogdan Miutescu</i></p> <p>2. How to overcome your first upper GI bleed - <i>Voicu Mercea</i></p> <p>3. Endotherapy for GI tract obstruction - <i>Teodor Voiosu</i></p> <p>4. Managing iatrogenic perforations in the GI tract - <i>Marcel Tanţău</i></p> <p>5. Quiz time – test your knowledge!</p>	<p>Session 3 PANCREAS Chair: <i>Ciprian Brisc, Zeno Spârchez, Ioan Sporea</i></p> <p>7. Transabdominal ultrasonography in pancreatitis. - <i>Larisa Săndulescu</i></p> <p>8. Ultrasonography in pancreatic tumors. Detection, role of CEUS&elastography, actual role of biopsy. - <i>Zeno Spârchez</i></p> <p>9. Pancreatic endoscopic ultrasound (EUS): technique, methodology, and biopsy. - <i>Adrian Săftoiu</i></p>	<p>Session 3 The art of suture without incision– Sutu Art - <i>As. med. Daciana Jurcan</i></p> <p>H. pylori-positive gastritis – The correlation between symptoms and endoscopic diagnosis - <i>As. med. Leni Ionescu</i></p> <p>When we cannot enter through the door, we find a window – An elegant alternative to ERCP: EUS-guided hepatic-gastrostomy - <i>As. med. Alexandru Pirvu</i></p> <p>Management of common bile duct stones from simple to complex - <i>As. med. Raluca Iana</i></p> <p>Therapeutic approaches in upper gastrointestinal bleeding in cirrhotic patients - <i>As. med. Costin Mangaru</i></p>
15:50-16:55	<p>AbbVie Symposium (60') AbbVie - Leading change in ulcerative colitis! - <i>Liana Gheorghe, Anca Trifan, Corina Pop</i></p>	<p>Medochemie Symposium (30') Redefining digestive comfort: the role of itopride in functional dyspepsia - <i>Mircea Diculescu</i></p> <p>Salveo Symposium (30') –Therapeutic management of hepatic encephalopathy in hospitalized patients and the importance of treatment continuation after discharge - <i>Dan Gheonea</i> –Targeting microbiota imbalance in IBS – New selective approach with Lactibiane Tolerance and Lactibiane Reference, - <i>Nara Nairi</i></p>		<p>Ferring Symposium (30') Optimization of the Ulcerative Colitis treatment - <i>Lucian Negreanu</i> How did biologics influence the treatment of ulcerative colitis - <i>Molnar Tamas</i></p> <p>Lilly Symposium (35') Patient-reported outcomes in ulcerative colitis: bringing bowel urgency and the urgency numeric rating scale into clinical practice - <i>Cristian Gheorghe, Mircea Diculescu</i></p>	

16:55-17:10

Coffee break ☕



THURSDAY JUNE 18TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
17:10-17:30	Rising Star Conference GEORGIANA GÎLCĂ - Beyond Algorithms in Gastroenterology: Art and Humanity Amidst Human Frailty				
17:30-19:00	<p>Session 4 COLORECTAL DISEASES</p> <p>Chair: Cristian Gheorghe, Dan Dumitraşcu, Dan Gheonea</p> <ol style="list-style-type: none"> 1. What are the changes recommended by Roma V in the bowel disorders of gut-brain interactions? - Dan Dumitraşcu 2. Early diagnosis and treatment in IBD - Cristian Gheorghe 3. Interval colorectal cancer: how to reduce the incidence? - Eugen Dumitru 4. Non-surgical treatment in diverticulitis - Dan Gheonea 	<p>Session 4 HCC RISK, SURVEILLANCE AND MANAGEMENT</p> <p>Chair: Zeno Spârchez, Speranta Iacob, Larisa Săndulescu</p> <ol style="list-style-type: none"> 1. Current surveillance recommendations and emerging strategies: Evolving concept of risk-based surveillance - Larisa Săndulescu 2. Patient-centered decision-making and treatment recommendation according to BCLC Update 2026 - Răzvan Cerban 3. Locoregional therapies for HCC: TACE, TARE - Mugur Grasu 4. Locoregional therapies for HCC: Ablation - Zeno Spârchez 5. Liver transplant for HCC - Speranța Iacob 	<p>Session MANAGING PATIENTS WITH OBESITY</p> <p>Chair: Thomas Horbach, Bogdan Mateescu, Dan Gheonea</p> <ol style="list-style-type: none"> 1. Expert insights: endoscopic vs surgical bariatric therapies: for whom, when, and why in 2026? - Thomas Horbach 2. Bariatric endoscopy – one year later - Bogdan Mateescu 3. Managing surgical complications - Vasile Şandru 4. Integrated obesity treatment in real clinical practice: complementary rather than competitive - Alina Spinean 	<p>Session 4 GASTROINTESTINAL TRACT</p> <p>Chair: Ioan Sporea, Ciprian Brisc, Radu Badea, Ioan Tofolean</p> <ol style="list-style-type: none"> 10. Ultrasonography in neoplastic diseases of the gastrointestinal tract. - Anda Leş 11. Ultrasonography in gastrointestinal emergencies – Acute diverticulitis and acute appendicitis - Roxana Sirlî 12. Ultrasonography in gastrointestinal emergencies – "The catastrophes" – Bowel obstruction, ischemia and perforation - Alina Popescu 	Gastroenterology Brainstorm Arena

19:00



Dinner Poiana Braşov Recreation Center –ACCESS ONLY WITH VOUCHER!



Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
8:00-9:30	<p>THE ROLE OF MULTI-DISCIPLINARY TEAM IN GASTROENTEROLOGY Chair: <i>Cristian Gheorghe, Mihai Ciocirlan, Oana Stănciulea</i></p> <p>1. The role of MDT in immun-mediated diseases</p> <p>1.1. At the crossroad of gastroenterology & dermatology - <i>Liana Gheorghe</i></p> <p>1.2 Challenges in the personalized management of patients with severe psoriasis and GI diseases - <i>Alin Nicolescu</i></p> <p>2. The role of MDT in early rectal cancer</p> <p>2.1. Endoscopist's point of view - <i>Mihai Ciocirlan</i></p> <p>2.2. Surgeon's point of view - <i>Florin Grama</i></p> <p>3. The role of MDT in stricturing ileal Crohn's disease</p> <p>3.1. Gastroenterologist's point of view - <i>Cristian Gheorghe</i></p> <p>3.2. Surgeon's point of view - <i>Oana Stănciulea</i></p> <p>4.OP: Postoperative cours eafter ileocolic resection in Crohn's disease: experience from a referral center - <i>Mihaela Topală, Oana Stănciulea, Loai Alshantti, Victor Ionescu, Cristian Gheorghe</i></p>	<p>HOT TOPICS IN HEPATOLOGY Chair: <i>Anca Trifan, Zeno Spârchez, Ciprian Brisc</i></p> <p>Introduction, <i>Anca Trifan</i></p> <p>1.Histotripsy in liver cancer - <i>Ciprian Brisc</i></p> <p>2.Role of viscoelastic tests before invasive procedures in liver cirrhosis - <i>Zeno Spârchez</i></p> <p>3.BAVENO VIII 2026: What's the new? - <i>Bogdan Procopeț</i></p> <p>4.Artificial intelligence revolution in epatology. - <i>Robert Năstăsă, Camelia Cojocariu</i></p> <p>5.The new realm: endohepatology - <i>Gheorghe Bălan, Anca Trifan</i></p> <p>6.OP: The prevalence of microvascular lesions in MASLD without cirrhosis - <i>Julia Minciună, Bogdan Procopeț</i></p> <p>7.OP: Effectiveness of essential phospholipidis, on liver function and quality of life in patients with steatotic liver disease: A prospective , multicenter, observational study - <i>Vlad Dumitru Brata, Darius Matei Caleniuc, Vlad Mercea, Alina Ioana Tanțău</i></p>	<p>VIDEOMARATHON Chair: <i>Mădălina Ilie, Gheorghită Bălan, Eugen Dumitru</i></p> <p>1. SEMS placement as a rescue endoscopic approach in complex esophageal defects: A two-case series. -<i>Ioana Popescu, Andrei Dumitru, Luana Alexandrescu, Gabriela Fricatel, Ilinca-Bianca Ghena, Eugen Dumitru</i></p> <p>2. Endoscopic vacuum therapy as rescue management for gastric fistula following sleeve gastrectomy: A case report after unsuccessful surgical treatment. -<i>Paul Cristian Borz, Ioana Mandroc, Lavinia Maria Tusan, Marcel Tanțău</i></p> <p>3. The leak that wouldn't close: The power of LAMS. - <i>Ioan Cristian Nedelcu, Raluca Cristina Monea, Beatrice Ioana Abramescu, Mariana Jinga</i></p> <p>4. Rescue LAMS for malpositioned biliary SEMS. <i>T. Pelehra, M. Rimbas, B. Mateescu, T. Voiosu</i></p> <p>5. Breaking barriers with EDGE: EUS access to distal cholangiocarcinoma after gastric bypass. - <i>Ana-Maria Buzuleac, Gheorghe Balan</i></p> <p>6. EUS-guided dual bypass: A one-session solution for pancreatic cancer obstruction – A case report. - <i>Raluca-Ioana Dascălu, Mădălina Ilie, Oana Plotogea, Christopher Pavel, Deniz Gunsahin, Vlad Rizescu, Gabriel Constantinescu</i></p> <p>7. Endoscopic ampullectomy: - A case series. <i>Vlad Iovănescu</i></p> <p>8. Recurrent intrahepatic lithiasis despite repeated surgical management successfully treated through endoscopic access creation: A case report. - <i>Marcel Tantau, Lavinia Tusan, Paul Borz, Ioana Mandroc, Mihai Ratan</i></p> <p>9. When the clip does not fire: Clip deployment failure during FTRD of a periappendiceal LST – A video case report. - <i>Delia Olteanu, Radu Bogdan Mateescu</i></p>	<p>ACUTE AND CHRONIC PANCREATITIS Chair: <i>Mariana Jinga, Cătălin Sfarti, Adrian Săftoiu, Alina Tanțău</i></p> <p>1. Timing of surgical Intervention in chronic pancreatitis - <i>Mihai Eftimie</i></p> <p>2. Integrated pain management in chronic pancreatitis - <i>Cătălin Sfarti</i></p> <p>3. Timing of invasive treatment in acute pancreatitis - <i>Adrian Săftoiu</i></p> <p>4. Five controversies versus five verdicts in acute pancreatitis management - <i>Vasile Daniel Balaban, Ioan Cristian Nedelciu</i></p> <p>5.OP: Prognostic value of red cell distribution width-to-platelet ratio in acute pancreatitis – multicenter registry cohort. - <i>Pahomeanu M.-R., Dumitru A., Gherasim A., Angelușiu A., Andreeana C., Bota A., Dumitrescu V., Gunsahin D., Stemate A., Țieranu C.G., Șandru V., Preda C.M., Dumitru E., Săftoiu A., Negreanu L.</i></p> <p>6.OP: Ex vivo Vivascope fluorescence confocal microscopy on EUS-FNB specimens in solid pancreatic lesions – prospective validation. - <i>Rednic V., Dragomir I., Hagiu C., Mosteanu O., Pojoga C., Seulean E., Orzan R., Fit A.-M., Rusu I., Rusu D., Petruschev B., Seicean A</i></p> <p>7.OP: Day 1 nucleated red blood cell count as a prognostic biomarker in acute pancreatitis – preliminary RO-API report. - <i>Pahomeanu M.-R., Andreeana C., Negreanu L.</i></p>	<p>INTESTINAL ULTRASOUND Chair: <i>Anda Leș, Ioan Tofolean</i></p> <p>1. Bowel ultrasound in IBD-diagnostic and complications - <i>Roxana Saizu</i></p> <p>2. Differential diagnosis in IBD - <i>Ioan Tofolean</i></p> <p>3. IUS in clinical practice - <i>Anda Leș</i></p> <p>Discussion</p>

FRIDAY JUNE 19TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
9:30-10:30	<p>Opella Symposium (15') The importance of active diagnosis and early initiation of therapeutic interventions in MASLD - <i>Liana Gheorghe</i></p> <p>Ipsen Symposium (45') Cholestatic liver diseases in clinical practice: challenges, controversies, and management strategies - <i>Liana Gheorghe, Răzvan Iacob</i></p>	<p>AbbVie Symposium (60') Leading change in Crohn disease! - <i>Cristian Gheorghe, Mircea Diculescu, Lucian Negreanu</i></p>		<p>Dicofarm Symposium (20') Evidence-based probiotic solutions - <i>Mircea Manuc</i></p> <p>Terapia Symposium (30') The patient with chronic constipation: from guidelines to practice - <i>Dan Dumitracu</i></p>	
10:30-10:45			Coffee break ☕		
10:45-12:15	<p>ULCERATIVE COLITIS OF OUR DAYS: ADVANCEMENTS IN DIAGNOSIS AND MANAGEMENT Chair: <i>Cristian Gheorghe, Anca Triřan, Lucian Negreanu</i></p> <ol style="list-style-type: none"> Lessons learned from IBD epidemiology - <i>Mircea Diculescu</i> Validated tools for risk stratification and therapeutic decision making - <i>Lucian Negreanu</i> Conventional treatment in patients with ulcerative colitis - <i>Adrian Goldiș</i> Advanced therapy for patients with ulcerative colitis - <i>Cristian Gheorghe</i> When to call the surgeon for ulcerative colitis - <i>Oana Stănculea</i> OP: A simple 3-point score predicts early hospitalization in newly diagnosed ulcerative colitis - <i>Ana-Maria Buzuleac, Horia Minea, Remus Stafie, Simona Juncu, Sabina Luca, Gheorghe Bălan, Anca Triřan, Ana-Maria Singeap</i> 	<p>AUTOIMMUNE & CHOLESTATIC LIVER DISEASES: NEW TOOLS, NEW TREATMENTS, AND SYMPTOMS MANAGEMENT Chair: <i>Dana Crișan, Liana Gheorghe</i></p> <ol style="list-style-type: none"> Advancements in therapy of autoimmune hepatitis: first line, second line, maintenance - <i>Irina Gîrleanu</i> Evolving PBC management: from biochemical response to holistic approach - <i>Mihaela Ghioca</i> PSC from diagnosis to liver transplantation – The unmet needs - <i>Andrada Seicean</i> Variant syndromes PBC/PSC-AIH and MASLD-AIH - <i>Liana Gheorghe</i> Management of extrahepatic co-morbidities - <i>Carmen Ester</i> Liver transplantation for autoimmune and cholestatic liver diseases - <i>Speranța Iacob</i> 	<p>COMPLICATIONS IN ENDOSCOPY Chair: <i>Gabriel Constantinescu, Teodor Voiosu</i></p> <p>A. Gabriel Constantinescu - TBD</p> <p>B. Alexandra Butnaru - Lessons from my first hybrid EMR</p> <ol style="list-style-type: none"> Endoscopic management of iatrogenic colonic perforation during balloon dilation in Crohn's disease: A video case. - <i>Olteanu Delia, Mateescu Bogdan</i> Tumor lysis syndrome after eus fnb - <i>Mihai Alexandru, Smeu Mare</i> Failed removal of foreign body in upper gi tract - <i>Alexandra Dumitrescu</i> 	<p>DIGESTIVE DISEASE AND AGEING – WHERE ARE WE GOING? Chair: <i>Cristina Cijevschi - Prelipcean, Gabriel Prada, Cătălina Miha</i></p> <ol style="list-style-type: none"> Introduction - <i>Cristina Cijevschi</i> Geriatrician's point of view - <i>Gabriel Prada</i> Artificial intelligence in the evaluation of digestive disease in elderly - <i>Iolanda Popa</i> IBD in elderly, ageing with IBD – what is the difference? - <i>Otilia Nedelciuc, Mihaela Dranga</i> Colorectal cancer in elderly: how to prevent it? Too much is too dangerous? - <i>Cătălina Raluca Nuta</i> How fast might the liver and the patient get older? - <i>Ovidiu Lucian Băjenaru</i> <p>Discussions</p>	<p>GASTRIC CANCER UP TO DATE Chair: <i>Simona Bataga, Ciprian Brisc, Mihai Ciocirlan</i></p> <ol style="list-style-type: none"> Prevention of gastric cancer - <i>Simona Bataga</i> Results from Togas EU Project - <i>Dan Dumitracu</i> Early gastric cancer management: EMR, ESD - <i>Mihai Ciocirlan</i> Advances in gastric cancer treatment - <i>Marius Ciorbă</i>
12:15-13:50	<p>Lilly Symposium (45') <i>Liana Gheorghe</i> Hearing the patient's voice: PROs as a clinical tool in ulcerative colitis management Moderator <i>Liana Gheorghe</i> - <i>Lukas Milan, Dan Gheonea, Anca Triřan</i></p> <p>Innergy Symposium (20') Biotic support and its importance in irritable bowel syndrome - <i>Liana Gheorghe, Dan Gheonea</i></p> <p>Novo Nordisk Symposium (30') MedTalks: The ESSENCE of Semaglutide in MASH - <i>Liana Gheorghe, Dan Gheonea</i></p>	<p>Krka Symposium (30') Proton pump inhibitors in gastroesophageal reflux disease. Management of GERD - <i>Bogdan Mateescu</i></p> <p>Opella Symposium (15') Optimizing therapy in irritable bowel syndrome with Drotaverine - <i>Felicia Coman</i></p> <p>Mayoly Symposium (30') The integrative approach in preparing the digestive tract for endoscopic and imaging explorations - <i>Camelia Bar, Elena Gologan</i></p> <p>Sobi Symposium (15') Avatrombopag: optimizing periprocedural management of thrombocytopenia in chronic liver disease - <i>Corina Pop</i></p>		<p>Secom Symposium (15') Gut-Liver synergy: clinical strategies for barrier restoration and detoxification support - <i>Lucian Negreanu</i></p> <p>Nestle Symposium (20') From sarcopenia and cachexia to nutritional rehabilitation and quality of life for patients with digestive disorders - <i>Mircea Diculescu</i></p> <p>Alfasigma Symposium (45') Clinical impact of non-systemic intestinal antibiotics' polymorphism - Rifaximine model - <i>Lucian Negreanu</i></p> <p>The Role of Rifaximin- α in the Management of Irritable Bowel Syndrome with Diarrhea (IBS-D) - <i>Bogdan Mateescu</i></p>	
13:50-14:45	Lunch Break 		RSDE General Assembly		

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
14:45-16:15	<p>CROHN'S DISEASE: KEY CONCEPTS IN DIAGNOSIS, MANAGEMENT AND MONITORING IN 2026 Chair: <i>Liana Gheorghe, Dan Gheonea, Alina Tanţău</i></p> <p>1. At the crossroad of endoscopy, histology and advanced imaging for the diagnosis of Crohn's disease - <i>Dan Gheonea</i></p> <p>2. Medical treatment in newly diagnosed Crohn's disease - <i>Liana Gheorghe</i></p> <p>3. Medical and surgical treatment in ileal Crohn's disease - <i>Anca Trifan, Horia Minea</i></p> <p>4. Postoperative monitoring in Crohn's disease - <i>Alina Tanţău</i></p> <p>5. Surgical treatment in perianal fistulas in Crohn's disease - <i>Florin Grama</i></p> <p>6. OP: The spectrum of perianal fistulas in Crohn's disease – real-life data from a single-center cohort. - <i>Cojocaru M, Bolboaca C, Gheorghe C.</i></p> <p>7. OP: Anxiety and depression in patients with inflammatory bowel disease using HADS scale - <i>Daria-Ana-Arina Gheorghe, Speranta Iacob, Andrei-Sorin Gherasim, Alexandru Rotaru, Alexandra Marinescu, Mihaela Ghioca, Carmen Ester, Roxana Saizu, Liliana-Simona Gheorghe, Cristian Gheorghe, Mircea Diculescu</i></p>	<p>MASLD – THE PANDEMIC OF OUR TIMES: FROM EPIDEMIOLOGY TO THERAPY Chair: <i>Carmen Fierbinteanu Braticevici, Ioan Sporea, Alina Popescu</i></p> <p>1. MASLD Epidemiology - <i>Dana Crişan</i></p> <p>2. Non-invasive diagnosis of MASLD – biochemical tests - <i>Larisa Săndulescu</i></p> <p>3. Non-invasive diagnosis of MASLD: elastography tests - <i>Alina Popescu</i></p> <p>4. Screening for MASLD in at-risk populations - <i>Ioan Sporea</i></p> <p>5. Current therapy of MASLD – pharmacological treatment, bariatric endoscopy, bariatric surgery - <i>Carmen Fierbinteanu Braticevici</i></p> <p>6. OP: Non-invasive risk stratification of MASLD in type 2 diabetes using simple clinical scores. - <i>Mare R, Bende R, Sporea I.</i></p>	<p>BASIC ENDOSCOPY TECHNIQUES IN REAL LIFE Chair: <i>Cătălin Sfarti, Bogdan Miuşescu, Mircea Mănuc</i></p> <p>1. Tips & tricks to improve quality of intubation and inspection of colorectal mucosa - <i>Ştefan Chiriac</i></p> <p>2. Colon polypectomy toolbox - <i>Cristian Tefas, Voicu Mercea</i></p> <p>3. Do I need deep sedation for all procedures? - <i>Ruxandra Mare</i></p> <p>4. Choosing the right accessories for hemostasis and resection – less is more? - <i>Ioan Cristian Nedelcu</i></p> <p>5. OP: Results from the CLEAN-AZ multicentric trial of azithromycin for upper GI bleeding - <i>Andrei Voiosu</i></p> <p>6. OP: Musculoskeletal symptoms and workplace ergonomics among digestive endoscopies in Romania: Cross-sectional survey. - <i>Topală M, Saizu I, Gheorghe C.</i></p> <p>7. OP: Detection and characterization gaps between external colonoscopy and tertiary trainee re-evaluation. - <i>Puiu M, Busuioc B, Tudor CM, Marin CG, Păun CA.</i></p> <p>8. The Many Faces of Enteroscopy: From Diagnosis to Therapy - <i>Marcel Tanţău, Ioana Mândroc</i></p>	<p>HOT TOPICS IN GASTROENTEROLOGY Chair: <i>Cătălina Mihai, Eugen Dumitru</i></p> <p>1. Fecal microbiota transplantation – indications and evolving reglementation - <i>Giorgiana Gilcă</i></p> <p>2. Up to date in Clostridioides difficile infection - <i>Cătălina Mihai</i></p> <p>3. Chronic mesenteric ischemia – a neglected entity - <i>Eugen Dumitru</i></p> <p>4. Pelvic floor disorders: an under-evaluated entity - <i>Anca Dimitru</i></p> <p>5. Immune-Mediated Colitis in the Era of Checkpoint Inhibitors. - <i>Petruţa Filip</i></p> <p>7. O.P Manometry-Guided Laparoscopic Heller Myotomy for Achalasia: Technical Standardization and Objective Outcome Validation in a Single-Team Experience - <i>Eftimie Mihai Adrian, Stănculea Oana Maria, Dimitriu Anca Mirela, Băncila Ion, Vrabie Elena-Mihaela, Moşteanu Iulian, Trotea Alexandra, Bădescu Bianca, Godja Andreea, Aranghelovici Călina, Abuzan-Constantin Cristina, Bălescu Irina, Potlog Gheorghe, Allob Ali, Stroescu Cezar, Bacalbaza Nicolae, Gheorghe Cristian, Braşoveanu Vladislav</i></p>	<p>ORAL PRESENTATION 2 Chair: <i>Răzvan Iacob, Vasile Balaban</i></p> <p>1. OP: Red cell distribution width at 24 hours as an early predictor of mortality and severity in acute pancreatitis - <i>Pistriţu A.F., Pahomeanu M.R., Nayerani H., Herdeş H., Birligea M., Bota A.D., Toma C.V., Preda C.M., Ţieranu C.G., Ionescu E.M., Mateescu R.B., Săftoiu A., Negreanu L.</i></p> <p>2. OP: Novel inflammatory indices (NFLI, MFLI) versus CA 19-9 for metastatic and histological stratification in PDAC - <i>Văcariu I.-A., Rogoveanu I., Ungureanu B.-S., Negulescu R.-F., Florescu D.-N., Iordache S., Vere C.-C.</i></p> <p>3. OP: Latent tuberculosis screening for IBD patients who received advanced therapy: Data from Fundeni Clinical Institute. - <i>Alexandru Ionut Rotaru, Alexandra Marinescu, Andrei Gherasim, Cristian Gheorghe.</i></p> <p>4. OP: Epidemiological trends in extraintestinal manifestations of Inflammatory Bowel Disease - <i>Carmen Atodiresei, Alina Ecaterina Jucan, Georgiana Elena Sârbu, Claudiu Vasile Mihai, Ioana Ruxandra Mihai, Mădălina Ene, Mihaela Dranga, Otilia Nedelciuc, Cristina Cijevschi Prelipcean, Alin Pinzariu, Cătălina Mihai</i></p> <p>5. OP: Estimates of the digestive cancers burden in the South-East side of Romania: an 8-year Retrospective analysis - <i>Rosca Robert, Luana Alexandrescu, Elena Dina, Andra Julia Suceveanu, Adrian Paul Suceveanu, Florin Musat, Andrei Dumitru, Ioan Tiberiu Tofolean, Eugen Dumitru, Cristina Tociu</i></p> <p>6. OP: Multidimensional assessment of health-related quality of life and fatigue in pediatric inflammatory bowel disease: an observational study - <i>Iuliana Alexandra Grigore, Ioana Dumitru, Alexandra Ilie, Alexandra Lozbă, Oana Marcu, Bianca Secară, Raluca Rădulescu, Mara Ioana Ionescu, Felicia Galoş</i></p>

FRIDAY JUNE 19TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
					7.OP: Assessment of intestinal barrier integrity by confocal laser endomicroscopy for relapse prediction in ileocolonic Crohn's disease - <i>Horia Minea, Carol Stanciu, Ana-Maria Singeap, Cătălin Sfarti, Stefan Chiriac, Gheorghe Bălan, Mihai Danciu, Raluca Avram, Oana Petrea, Cristina Muzică, Laura Huiban, Simona Juncu, Remus Stafie, Ana-Maria Buzuleac, Andreas Savin, Robert Nastasa, Ermina Stratina, Adrian Rotaru, Camelia Cojocariu, Anca Trifan</i>
16:15-17:45	<p>THE ROLE OF PATHOLOGIC REPORT IN GASTROENTEROLOGY: WHAT EVERY GASTROENTEROLOGIST SHOULD KNOW Chair: <i>Gabriel Beceanu, Cristian Gheorghe, Bogdan Cotruță</i></p> <p>1. Cross talk: Liver biopsy: when, why, in whom? - <i>Liana Gheorghe, Gabriel Beceanu</i></p> <p>2. Cross talk: Difficult diagnosis in gastric tumors (infiltrating lesions extramucosal lesions, atypical ulcer) - <i>Cristina Tocia, Gabriel Beceanu</i></p> <p>3. Cross talk: IBD what to expect from pathologist - <i>Cristian Gheorghe, Mona Dumbrava</i></p> <p>4. Cross talk: Colorectal Polyps: how to elaborate and how to understand the pathologic report - <i>Bogdan Cotruță, Mona Dumbrava</i></p>	<p>CIRRHOSIS AND COMPLICATIONS Chair: <i>Ion Rogoveanu, Ana Maria Singeap, Liana Gheorghe</i></p> <p>1. What's new in beta-blockers therapy for portal hypertension? - <i>Ion Rogoveanu</i></p> <p>2. Spontaneous bacterial peritonitis in the era of multidrug resistance: therapeutic challenges and evolving strategies - <i>Ana-Maria Singeap, Simona Juncu</i></p> <p>3. Nutrition, sarcopenia, and frailty in cirrhosis - <i>Liana Gheorghe, Mihaela Ghioca</i></p> <p>4. Management of electrolyte disorders in decompensated cirrhosis - <i>Roxana Şirli</i></p> <p>5.OP: Five-day mortality in active upper GI bleeding: comparative analysis between 2015 and 2025 in a tertiary centre. - <i>Gherasim AS, Cotruța B, Băncilă I, Cojocaru M, Saizu I, Saizu R, Stroe T, Preda C, Meianu C, Ciora C, Dimitriu A, Topală M, Gheorghe C.</i></p> <p>6.OP: Early rebleeding after evl is not a single entity: distinct phenotypes, predictors, and outcomes. - <i>Juncu S, Singeap A.M., et al</i></p>	<p>ETHICS AND MALPRAXIS IN DIGESTIVE ENDOSCOPY Chair: <i>Mariana Jinga, Mihai Ciocirlan, Ofelia Moşteanu, Elena Toader</i></p> <p>1. Criminal liability for malpractice - <i>prosecutor Simona Anghel</i></p> <p>2. Endoscopy without error or endoscopy without liability? - <i>lawyer Cătălina Bordianu</i></p> <p>3. The doctor-patient relationship in the social media era - <i>Horia-Roman Patapievici</i></p> <p>4. Discussions</p>	<p>HEREDITARY COLORECTAL CANCER SYNDROMES Chair: <i>Răzvan Iacob, Daniela Dobru, Elena Toader</i></p> <p>1. Adenomatous polyposis coli: advancement in diagnosis and management - <i>Daniela Dobru</i></p> <p>2. Lynch Syndrome the gastroenterologist's perspective - <i>Răzvan Iacob</i></p> <p>3. Advances in molecular tools for the genetic diagnosis of colorectal cancer - <i>Dragoş Cretoiu</i></p> <p>4. Ethical principles in communication and decision making in patients with hereditary CRC syndromes - <i>Elena Toader</i></p> <p>5. Integrating molecular pathology in the diagnosis of hereditary colorectal cancer - <i>Gabriel Beceanu</i></p> <p>6.OP: Supporting the Fundeni Hereditary Colorectal Cancer Registry Development through AI technology - <i>Ştefana Drăgan, Roxana Neamţu, Mihaela Topală, Alexandru Rotaru, Cristian Gheorghe</i></p>	<p>NONINVASIVE TESTS IN CHRONIC LIVER DISEASES Chair: <i>Ioan Sporea, Bogdan Procopeţ</i></p> <p>1. Biological tests in chronic hepatopathies - <i>Alina Popescu</i></p> <p>2. Quantification by ultrasound of hepatic steatosis and inflammation - <i>Ioan Sporea</i></p> <p>3. Ultrasound-based elastography of the liver and spleen - <i>Bogdan Procopeţ</i></p> <p>4. Quantification of steatosis and fibrosis liver by MRI-TBA</p>

FRIDAY JUNE 19TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
17:45-18:00	Coffee break ☕				
18.00-19:30	<p>EFFECTIVE COLORECTAL CANCER SCREENING : HOW TO INCREASE THE ADHERENCE ? Chair: <i>Cristian Gheorghe, Carmen Ungurean, Mircea Mănuș</i></p> <ol style="list-style-type: none"> FIT-based screening or colonoscopy-based screening program for colorectal cancer prevention ? - <i>Mircea Mănuș</i> What did we learn from the pilot colorectal cancer screening program (ROCCAS) preparing national extension from 2025-2029 - <i>Cristian Gheorghe</i> T1 colorectal cancer endoscopic resection : data from ROCCAS pilot program - <i>Bogdan Cotruță</i> Overcoming barriers in upcoming colonoscopy as part of colorectal cancer screening programs - <i>Carlo Senore</i> <p>Discussions</p>	<p>SPECIAL TOPICS IN HEPATOLOGY Chair: <i>Corina Pop, Adriana Cavasi, Olga Orășan</i></p> <ol style="list-style-type: none"> Drug induced liver injury in 2026 - <i>Adriana Cavasi</i> Liver diseases of pregnancy - <i>Corina Pop</i> Cholangiocarcinoma - <i>Tudor Mocan</i> IgG4-Related Cholangitis: Challenges in Diagnosis and Management - <i>Olga Orășan</i> OP: Bulevirtide improves hepatitis-specific quality of life at 12 months in chronic HDV. - <i>Liana Gheorghe, Mihaela Ghioca, Mirela Onica, Daria-Ana-Arina Gheorghe, Anca Trifan, Laura Huiban, Larisa Săndulescu, Dan Gheonea, Corina Radu, Bogdan Procopeț, Roxana Șirli, Corina Pop, Nicoleta Tiuca, Bogdan Silviu Ungureanu, Adina Turcu-Stiolica, Speranța Iacob</i> OP: Viral hepatitis B, C, D in previously unknown patients in private laboratories: Data from Re-link project - <i>Speranța Iacob, Antoanela Curici, Liliana Gheorghe</i> OP: Clinical Characteristics and Severity Correlation in Patients with Concomitant Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Retrospective Cohort – Study. - <i>Roxana Saizu, Daria-Ana-Arina Gheorghe, Mihaela Ghioca, Speranța Iacob, Liana Gheorghe</i> 		<p>PSIHOASTROENTEROLOGY Chair: <i>Simona Grad, Dan Dumitrașcu, Paul Porr</i></p> <ol style="list-style-type: none"> New standards in GERD: the CNS-ENS issues - <i>Simona Grad</i> Empirical and directed at symptoms treatment in functional dyspepsia - <i>Laurențiu Nedelcu</i> The management of chronic nausea and emesis - <i>Liudmila Tofan-Scutaru</i> Biomarkers in IBS - <i>Abdulrahman Ismaiel</i> Microbiota and the gut-brain interaction - <i>Ovidiu Frățilă</i> Psychosomatic phenotypes of diverticular disease - <i>Cristina Sabo</i> 	<p>JOINT SESSION 1 Chair: <i>Elena Toader, Mircea Diculescu (R. Moldova)</i></p> <ol style="list-style-type: none"> Anti-Helicobacter Therapy in 2026: Facts and Challenges in the Republic of Moldova - <i>Eugen Tcaciuc</i> Gluten-associated disorders: from myths to scientific evidence - <i>Svetlana Turcan, Alina Jucov</i> Can we treat MASLD by scavenging ammonia? a systematic review of l-ornithine l-aspartate - <i>Abdulrahman Ismaiel</i> OP: Efficacy of helicobacter pylori eradication therapies in the republic of moldova: an observational study - <i>Eugen Tcaciuc, Doina Surguci, Cătălina Olaru-Stăvilă, Angela Tcaciuc, Cristina Pirvu, Denis Ardeleanu</i> OP: Growth failure at diagnosis as a predictor of severe disease in pediatric inflammatory bowel disease - <i>Alexandra Lozbă, Oana Marcu, Bianca Secară, Alexandra Ilie, Ioana Dumitru, Iuliana Crigore, Raluca Rădulescu, Mara Ionescu, Felicia Galoș</i> OP: Prescribing and deprescribing practices of proton pump inhibitors - <i>Ioana-Sânziana Glavan, Daniel-Vasile Balaban, Virgil-Andrei Godeanu, Marina Balaban, Mariana Jinga</i>
19:30-20:15	SRGH GENERAL ASSEMBLY				
20:15	Dinner 🍷 Poiana Braşov Recreation Center ACCESS ONLY WITH VOUCHER! 🎟				

SATURDAY JUNE 20TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
8:30-10:00	<p>RECTAL CANCER Chair: <i>Cristian Gheorghe, Victor Tomulescu, Vasile Binţinţan</i></p> <p>1.Role of endoscopy in the pre- and post-therapeutic evaluation of rectal cancer - <i>Cristian Gheorghe</i></p> <p>2.IRM for rectal cancer staging - <i>Iulia Grecu</i></p> <p>3.Multidisciplinary management of rectal cancer. Therapeutic strategies in 2026 - <i>Adina Croitoru</i></p> <p>4.Principles of oncologic surgery in rectal cancer with sphincter saving - <i>Vasile Binţinţan</i></p> <p>5.Robotic surgery for rectal cancer - <i>Victor Tomulescu</i></p>	<p>LIVER TRANSPLANT & SURGERY FOR CIRRHOTIC PATIENTS Chair: <i>Speranţa Iacob, Irina Gîrleanu, Horia Ştefănescu</i></p> <p>1.When should I refer to a liver transplant center? Early referral in 2026 - <i>Horia Ştefănescu</i></p> <p>2.Practical risk assessment and optimization for non-hepatic surgery in cirrhosis in 2026 - <i>Ana Maria Singeap</i></p> <p>3.Recognizing the transplant window in ACLF - <i>Irina Gîrleanu, Cristina Muzica</i></p> <p>4.Post-liver transplant shared care: The gastroenterologist's role in long-term monitoring - <i>Speranţa Iacob</i></p>	<p>HOW TO APPLY ADVANCED ENDOSCOPY TECHNIQUES IN REAL LIFE Chair: <i>Vasile Drug, Andrada Seicean, Adrian Săftoiu</i></p> <p>1.Romanian ESD Registry - <i>Ioan Cristian Nedelcu, Mihai Ciocîrlan</i></p> <p>2.Endoscopic ultrasound drainages of pancreatic fluid collections - Promises, pitfalls and practice - <i>Mădălina Ilie, Gheorghe Bălan</i></p> <p>3.Endoscopic ultrasound hepaticogastrotomy - The Romanian recipe - <i>Andrada Seicean, Teodor Voiosu, Voicu Rednic</i></p> <p>4.AI structured reporting and quality control - <i>Adrian Săftoiu, D. Burtea, Mircea Mănuç</i></p> <p>5.OP: Objective assessment of pancreatic microvascular density using computer-assisted detective flow imaging endoscopic ultrasonography. - <i>Tăbăcelia D, Voiosu T, Robles-Medrandă C, et al.</i></p> <p>6.OP: Endoscopic ultrasound hepaticogastrotomy – The Romanian recipe - <i>T. Voiosu, V. Rednic, A. Balintescu, T. Pelehra, A. Seicea</i></p>	<p>NEUROGASTROENTEROLOGY Chair: <i>Teodora Surdea-Blaga, Ioan Băncilă, Vasile Drug</i></p> <p>1.Diagnosis and surgical indications for hiatal hernia - <i>Teodora Surdea-Blaga</i></p> <p>2. Microscopic colitis overlapping IBS - <i>Flaviu Rusu</i></p> <p>3. Anorectal functional disorders after colorectal surgery - <i>Anca Dimitriu</i></p> <p>4. Recent recommendations for the diagnosis and treatment of laryngopharyngeal reflux disease - <i>Ion Băncilă</i></p> <p>5.Safety Profile of Antisecretory Drugs in GERD - <i>Diana-Elena Floria, Mahmoud Obeidat, Balint Eross, Oana-Bogdana Barboi, Radu Vulpoi, Vadim Roşca, Vasile Liviu Drug</i></p> <p>6.Decoding Functional Dyspepsia: A New MRI-Based Window into Gastric Function - <i>Vadim Roşca, Asbjorn Mohr Drewes, Esben Mark, Liao Donghua, Camelia Cojocariu, Oana Barboi, Radu Vulpoi, Roxana Rusu, Liliana Gheorghe, Diana Floria, Constantin Simiras, Vasile Drug and Aalborg</i></p>	<p>JOINT SESSION 2 (R. Moldova) Chair: <i>Dan Dumitrascu, Liana Gheorghe</i></p> <p>1. IgG4-Related Liver Disease: Diagnostic Challenges and Lessons from Clinical Cases - <i>Adela Turcan</i></p> <p>2. The impact of infections on the evolution and prognosis of alcoholic hepatitis - <i>Elena Berliba</i></p> <p>3. Delta hepatitis in the transplant era: Lessons from the Moldovan National Program - <i>Angela Peltec</i></p> <p>4.OP: Liver and spleen viscoelastic properties in de novo MASLD after liver transplantation: A 2D-SWE study. - <i>Cristina Muzica, Anca Trifan</i></p> <p>5.OP: Age dominates over gut-liver axis markers in ASCVD risk stratification among MASLD patients: a prospective two-cohort European study. - <i>Ciurea NA, Băjagă S</i></p>
10:00-11:00	<p>AstraZeneca Symposium (40') Navigating the dynamic landscape of HCC: Challenges and opportunities - <i>Liana Gheorghe</i> Himalaya Study: Evolving uHCC treatment outcomes with STRIDE regimen - <i>Adina Croitoru</i></p> <p>AstraZeneca Symposium (20') Current standard practice and emerging innovations in onco-surgical management of resectable gastric/GEJ cancers - <i>Tudor Grigorie</i></p>	<p>Dr.Reddy's Symposium (20') Place of Lactiplantibacillus plantarum 299V (LP299V®) in bowel disorders - <i>Lucian Negreanu</i></p> <p>Dr.Reddy's Symposium (20') Multimodal liver protection - the role of synergy between ingredients - <i>Mihaela Cristina Olariu</i></p>			
11:00-11:15	Coffee break ☕				

SATURDAY JUNE 20TH 2026

DETAILED SCIENTIFIC PROGRAM

Room/ Hour	K2 Events Center Conference Room ATLAS	K2 Events Center Conference Room URAL	Hotel Sportul BALLROOM	K2 Events Center Conference Room ALTAI	K2 Events Center Conference Room PAMIR
11:15-12:45	<p>PANCREATIC SOLID LESIONS Chair: <i>Cristian Gheorghe, Andrada Seicean, Mihai Ciocirlan</i></p> <p>1. Fatty pancreas: diagnosis and management - <i>Andrada Seicean</i></p> <p>Pancreatic cancer screening Checklist to identify high-risk patients - <i>Cristian Gheorghe</i></p> <p>3. Pros and Cons in pancreatic cancer: EUS tissue acquisition - <i>Cătălina Vlăduț, Mihai Ciocirlan,</i></p> <p>4. Pros and Cons in pancreatic cancer: preoperative biliary drainage - <i>Sergiu Cazacu, Vlad Iovănescu</i></p> <p>5. Infected won't does an upfront necrosectomy improves the outcome? - <i>Simina Ratan, Edina Seulean, Rares Orzan, Voicu Rednic, Cristina Pojoga, Serban Seicean, Vlad Mercea, Irina Dragomir, Geza Molnar, Nadim Al Hajjar, Andrada Seicean</i></p>	<p>PREDICTION IN HEPATOLOGY Chair: <i>Roxana Şirli, Larisa Săndulescu, Corina Radu</i></p> <p>1. Predicting Fibrosis Progression: From Non-Invasive Tools to AI - <i>Roxana Şirli</i></p> <p>2. Predicting HCC Risk: Toward Personalized Surveillance Strategies - <i>Larisa Săndulescu</i></p> <p>3. Artificial Intelligence in Hepatology: From Promise to Practice - <i>Ioan Sporea</i></p> <p>4. Predictive insights into the progression of Primary Biliary Cholangitis - <i>Corina Radu</i></p> <p>5. Predictive factors in the evolution of chronic hepatitis B infection - <i>Dana Matei</i></p>	<p>BEST ABSTRACTS Chair: <i>Bogdan Mateescu, Lucian Negreanu</i> BEST ABSTRACTS Chair: <i>Bogdan Mateescu, Lucian Negreanu</i></p> <p>1.0P: Endoscopic sleeve gastroplasty: learning curve and 12-month outcomes during early programme implementation in a tertiary eastern european centre - <i>Delia Olteanu, Radu Bogdan Mateescu, Sorina Telescu</i></p> <p>2.0P: Interobserver variability in screening colonoscopy quality assessment: implications for clinical management and ai-based objective evaluation - <i>Radu Alexandru Vulpoi, Mihaela Luca, Adrian Ciobanu, Oana-Bogdana Bărboi, Diana-Elena Floria, Vadim Roşca, Bălan Gheorghe, Olteanu Andrei, Gheorghe Cristian, Dumitru Eugen, Vasile-Liviu Drug</i></p> <p>3.0P: Comparing the diagnostic accuracy of EUS, CT and MRI in detecting small pancreatic lesions – systematic review and meta-analysis. - <i>Grigorovici R., Lee J., Obeidat M., Brand T., Hegyi P.J., Eross B., Bunduc Chirilov S. Sfarti C.V., Hegyi P.</i></p> <p>4.0P: Impact of EUS-FNB derived tumor size and Ki-67 on clinical management of pancreatic neuroendocrine tumors - <i>Seicean S., Pojoga C., Mostean O., Hagiu C., Munteanu L., Rednic V., Dragomir I., Al Hajjar N., Molnar G., Fit A.-M., Petrushev B., Seicean A</i></p> <p>5.0P: Beyond the pancreas: cardiovascular complications as predictors of mortality in acute pancreatitis. - <i>Tantu D, Bunduc Chirilov S., Gheorghe C</i></p>	<p>What's NEW in NETS ? Chair: <i>Cătălina Poiana, Adina Croitoru, Mircea Diculescu</i></p> <p>1. New Approaches from the endocrinologist - <i>Cătălina Poiana</i></p> <p>2. The place of the Gastroenterologist in Colorectal NETs in 2026 - <i>Mircea Diculescu</i></p> <p>3. Systemic treatments of NETs - <i>Adina Croitoru</i></p> <p>Clinical case report 1</p> <p>Clinical case report 2 (Gastroenterology)</p> <p>Clinical case report 3 (Oncology)</p>	<p>Oral Presentation 2 Chair: <i>Ion Dina, Simona Bataga</i></p> <p>1.0P: Does a prior malignancy influence outcomes in pancreatic cancer? Demographic, clinical and survival prospective analysis - <i>Marinescu A, Bunduc Chirilov S, Saizu IA, Gheorghe C</i></p> <p>2.0P: Impact of cirrhosis etiology on clinical outcomes and healthcare costs: 3-year retrospective study. - <i>Todor AP, Alina Popescu</i></p> <p>3.0P: Cutaneous 7 inflammatory bowel disease: clinical spectrum and therapeutic implications - <i>Alexandra Marcu, Corina Meianu, Tudor Stroie, Doina Istrătescu, Mircea Diculescu</i></p> <p>4.0P: Cumulative ionizing radiation exposure in inflammatory bowel disease patients under advanced biological therapy – a tertiary center analysis - <i>Rares Marian Moisiuc, Maria-Cosmina Alexe, Andreea-Daniela Bota, Adela Stanciu, Adrian Săftoiu, Cristian-George Ţieranu</i></p> <p>5.0P: Mmanometric parameters and clinical risk factors associated with gerd symptom burden and erosive severity in a prospective monocentric cohort - <i>Denis Ardeleanu, Eugen Căciuc, Viorel Istrăte, Cătălina Olaru-Stăvilă</i></p> <p>6.0P: Mismatch repair deficiency in colorectal cancer: associations with tumor features and inflammatory markers - <i>Gina Gheorghe, Vlad Alexandru Ionescu, Ioana Alexandra Baban, Alexandru Barbu, Ninel Iacobus Antonie, Teodor Florin Georgescu, Răzvan Matei Bratu, Carmen Cristina Diaconu, Cristina Mambet, Coralia Bleotu, Valentin Enache, Camelia Cristina Diaconu</i></p>

12:45-13:00

Closing Session and Award Ceremony

START STRONG. STAY STRONG.

WELL-ESTABLISHED

SAFETY PROFILE.*



INDICAȚII¹

Colită ulcerativă

Skyrizi este indicat pentru tratamentul pacienților adulți cu colită ulcerativă activă moderată până la severă care au avut un răspuns inadecvat, au pierdut răspunsul sau au manifestat intoleranță la terapia convențională sau la terapia biologică.

Boală Crohn

Skyrizi este indicat pentru tratamentul pacienților adulți cu boală Crohn activă moderată până la severă care au avut un răspuns inadecvat, au pierdut răspunsul sau au manifestat intoleranță la terapia convențională sau o terapie biologică.

RCP SKYRIZI®



***START STRONG: CU.** Date din studiul INSPIRE: răspuns clinic la săptămâna 4 (INSPIRE - $P < 0,0001$), vindecare a mucoasei la săptămâna 12 ($P < 0,0001$); **BC.** Răspuns clinic îmbunătățit (SF/APS) la săptămâna 4 (studiul ADVANCE - $P < 0,01$, studiul MOTIVATE - $P < 0,05$), vindecare a mucoasei la săptămâna 12 (studiul ADVANCE - $P < 0,001$, studiul MOTIVATE - $P < 0,01$);²

STAY STRONG: CU. Date din studiul COMMAND: remisiune clinică în populația totală la săptămâna 52 ($P < 0,01$), remisiune clinică la săptămâna 52 pentru pacienții AT-naivi; menținere a remisiunii clinice la săptămâna 52 ($P < 0,01$ pentru SKYRIZI 180 mg și $P = 0,2234$ pentru SKYRIZI 360 mg), vindecare a mucoasei în populația totală la săptămâna 52 ($P < 0,01$), vindecare a mucoasei la săptămâna 52 pentru pacienții AT-naivi; **BC.** Date din studiul FORTIFY: menținere a remisiunii clinice la săptămâna 52 ($P < 0,01$), vindecare a mucoasei la săptămâna 52 ($P < 0,01$);²

WELL ESTABLISHED SAFETY PROFILE: CU. Date de siguranță la săptămâna 12 din studiul INSPIRE, date de siguranță la săptămâna 52 din studiul COMMAND; **BC.** Date de siguranță la săptămâna 12 din studiile ADVANCE și MOTIVATE, date de siguranță la săptămâna 52 din studiul FORTIFY.²

IBD - Boală inflamatorie intestinală, CU - colită ulcerativă, BC - boală Crohn,

Referințe: 1. **SKYRIZI**® - Rezumatul caracteristicilor produsului, pentru vizualizare scanați cod QR; 2. **RINVOQ**® - Rezumatul caracteristicilor produsului, pentru vizualizare scanați cod QR.

Acest material promoțional este destinat profesioniștilor din domeniul sănătății.

Pentru informații medicale suplimentare va puteți adresa la e-mail: informatiimedicala@abbvie.com. Profesioniștii din domeniul sănătății sunt rugați să raporteze la AbbVie se poate face către Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România (ANMMDR), e-mail: adr@anm.ro, website: www.anm.ro

RINVOQ®: Deținătorul autorizației de punere pe piață (DAPP): AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germania. Nr. APP: EU/1/19/145 mg. Data primei autorizări sau a reînnoirii autorizății: 16 Decembrie 2019. Data revizuirii textului: scanează codul QR.

SKYRIZI®: Deținătorul autorizației de punere pe piață (DAPP): AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germania. Nr. APP: EU/1/19/1361/007 - Skyrizi 180 mg soluție injectabilă în cartuș și EU/1/19/1361/007 - Skyrizi 360 mg soluție injectabilă în cartuș. Data primei autorizări sau a reînnoirii autorizății: 16 Decembrie 2019.

IBD is NOW!



FAST. DURABLE. MUCOSAL HEALING.**

RCP RINVOQ®



INDICAȚII²

Colită ulcerativă

RINVOQ este indicat pentru tratamentul colitei ulcerative active, moderată până la severă, la pacienții adulți care au avut un răspuns inadecvat, nu au mai răspuns sau au prezentat intoleranță la terapia convențională sau la un medicament biologic.

Boală Crohn

RINVOQ este indicat pentru tratamentul bolii Crohn active, moderată până la severă, la pacienții adulți care au avut un răspuns inadecvat, nu au mai răspuns sau au prezentat intoleranță la terapia convențională sau la un medicament biologic.

****FAST: CU.** Răspuns clinic conform scorului Mayo adaptat parțial la săptămâna 2 de inducție ($P < 0,0001$); **BC: CR-100** (răspuns clinic 100: scădere cu ≥ 100 de puncte a scorului Crohn's Disease Activity Index față de momentul inițial) la săptămâna 2 de inducție ($P < 0,01$);¹

DURABLE: CU. Menținerea remisiunii clinice conform scorului Mayo adaptat la săptămâna 52 ($P < 0,001$); **BC:** menținerea remisiunii clinice (scor frecvență scaune/durere abdominală) la săptămâna 52 ($P < 0,001$);¹

MUCOSAL HEALING: CU. Subscor endoscopic ≤ 1 fără friabilitate la săptămâna 8 de inducție și la săptămâna 52 de întreținere ($P < 0,001$). **BC:** Subscorul suprafeței ulcerate SES-CD de 0 la pacienții cu subscorul suprafeței ulcerate SES-CD ≥ 1 la momentul inițial, la săptămâna 12 de inducție și la săptămâna 52 de întreținere ($P < 0,001$).¹

Utilizare scanați cod QR.

Reacții adverse suspectate. Raportarea evenimentelor adverse suspectate pentru produsele sau către AbbVie SRL, Tel.: +40215293429 / E-mail: farmacovigilenta_romania@abbvie.com.

9/1404/001 – Rinvoq 15 mg, EU/1/19/1404/006 – Rinvoq 30 mg și EU/1/19/1404/010 – Rinvoq

9/1361/004 - Skyrizi 600 mg concentrat pentru soluție perfuzabilă în flacon, EU/1/19/1361/005 -
la prima autorizare: 26 Aprilie 2019. Data revizuirii textului: scanează codul QR.

abbvie

ABBVIE S.R.L.

Lake View, Strada Barbu Văcărescu nr. 301-311

Etaj 2, Sector 2, C.P. 020276, București, România


Tel: +4021 529 3035/ Fax: +4021 529 3031

RO-IMMG-260009 || Mai 2026

Mounjaro: singurul agonist al receptorilor GIP și GLP-1 aprobat pentru controlul greutateii

ÎN SURMOUNT-5 Mounjaro[®] a demonstrat reducere superioară a greutateii comparativ cu semaglutida²

La săptămâna 72, **participanții tratați cu Mounjaro DMT (10 mg sau 15 mg) au înregistrat o reducere medie superioară a greutateii de -21,6%^a comparativ cu -15,4%^a la cei tratați cu semaglutidă în doză maximă tolerată (1,7 mg sau 2,4 mg)^{2;§,1}**



^aDatele sunt prezentate ca medie a celor mai mici pătrate cu un interval de încredere de 95% sau ca procente. Doar datele la săptămâna 72 au fost prespecificate și verificate pentru multiplicitate.²

Studiul SURMOUNT-5 a comparat tirzepatida DMT (10 mg sau 15 mg) și semaglutida DTM (1,7 mg sau 2,4 mg), doza maximă aprobată de semaglutidă pentru controlul greutateii la momentul inițierii studiului. Semaglutida 7,2 mg nu a fost evaluată în acest studiu. DMT=doza maximă tolerată

▼Acest medicament face obiectul unei monitorizări suplimentare. Acest lucru vă permite identificarea rapidă de noi informații referitoare la siguranță. Profesioniștii din domeniul sănătății sunt rugați să raporteze orice reacții adverse suspectate. Raportați o reacție adversă către: Lilly: phv_centre_see@lilly.com; ANMDM: adr@anm.ro

*SURMOUNT-5 a fost un studiu de fază 3b, cu durată de 72 de săptămâni, multicentric, randomizat, cu brațe paralele, deschis, controlat cu comparator, care a evaluat eficacitatea și siguranța Mounjaro 15 mg sau a dozei maxime tolerate (10 mg sau 15 mg) comparativ cu Semaglutida 2,4 mg sau doza maximă tolerată (1,7 mg sau 2,4 mg) la adulți cu obezitate (IMC ≥ 30 kg/m²) sau supraponderali (IMC ≥ 27 kg/m²) cu cel puțin o complicație asociată obezității (de exemplu, hipertensiune, dislipemie), excluzând diabetul.² Limitările unui studiu deschis pot fi legate de un posibil bias în evaluarea rezultatelor, eficacității și/sau siguranței, iar analiza nu a fost comparată cu un grup de control placebo.² [§]Estimarea eficacității, populația mITT, analiză MMRM.²

1. Mounjaro Rezumatul Caracteristicilor Produsului, ultima variantă disponibilă; 2. Aronne LJ, et al. N Engl J Med. Published online ahead of print, May 12, 2025.

Acest material este destinat profesioniștilor din domeniul sănătății.

PP-TR-RO-0636



WE ARE LEADING A REVOLUTION IN ONCOLOGY TO REDEFINE CANCER CARE



Acest material promoțional este destinat profesioniștilor din domeniul sănătății.

Pentru informații suplimentare, vă rugăm să consultați versiunea actualizată a Rezumatul Caracteristicilor Produsului, scanând codul QR.

▼ Medicamentele Enhertu, Imjudo, Truqap, Datroway fac obiectul unei monitorizări suplimentare. Acest lucru va permite identificarea rapidă de noi informații referitoare la siguranță. Profesioniștii din domeniul sănătății sunt rugați să raporteze orice reacții adverse suspectate.

Evenimentele adverse pot fi raportate online <https://contactazmedical.astrazeneca.com>, sau la adresa farmacovigilenta@astrazeneca.com

Medicamente eliberate pe bază de prescripție medicală.



AstraZeneca Pharma S.R.L.
Str. Tipografilor 1A, MUSE Offices, Et. 2 și 3., 013714, sector 1, București
Tel.: +40 21 317 60 41; office.romania@astrazeneca.com

RO-28244/10.2025

PiLeJe
LABORATOIRE

LACTIBIANE

SINDROMUL INTESTINULUI IRITABIL - IBS

LACTIBIANE

Référence

AMELIORAREA
CONSTIPAȚIEI ÎN IBS-C¹



+32%

CREȘTERE A FRECVENȚEI
SCAUNELOR DUPĂ
PRIMA LUNĂ DE
ADMINISTRARE¹

LACTIBIANE

Tolérance

SUPPORT ÎN EPISOADELE
DIAREICE ÎN IBS-D SAU
DE ALTERNANȚĂ
DIAREE-CONSTIPAȚIE ÎN IBS-M²



-72,2%

REDUCERE A
PERMEABILITĂȚII
PATOLOGICE ÎN IBS, A
BARIEREI INTESTINALE,
DUPĂ 5 ORE²



Certificat HQM – garanția
tulpinilor microbiotice de
calitate

Acest material este destinat profesioniștilor din domeniul sănătății. Produsele PiLeJe Lactibiane sunt suplimente alimentare. Citiți cu atenție informațiile de pe ambalaj. Suplimentele alimentare nu înlocuiesc o dietă variată și echilibrată și un stil de viață sănătos. A nu se lăsa la îndemâna copiilor mici. A nu se depăși doza recomandată. A se păstra în ambalajul original, la temperaturi între 15-25°C, în locuri ferite de umiditate. Producător ATB, REFERENCE, TOLERANCE-PILEJE INDUSTRIE, Neuropole, ZA les Toulans, 03800 Saint Bonnet de Rochefort, Franța. Producător Imedia: LALLEMAND SAS - 4 chemin du bord de l'eau - 15130 SAINT SIMON, Franța. Deținător noticare: Salveo Romania s.r.l., Str. Tipograful Nr. 11-15, Clădirea B4, Etaj 5, Sector 1, București.

HP-RO-141-05/2026

1. Drouault-Holowacz S et al. Gastroenterologie clinique et biologique. 2008;32(2):147-52
2. Nebot-Vivinus M et al. World Journal of Gastroenterology. 2014;20(22):6832-43


SALVEO

ESSENTIALE® MAX

EXCEL: NOUL NOSTRU STUDIU CLINIC



Primul studiu clinic randomizat, în regim dublu-orb, controlat cu placebo, axat pe eficacitatea fosfolipidelor esențiale la pacienții cu MASLD.^{*1,2,5}

2,5x

MAI EFICIENT

ÎN REDUCEREA STEATOZEI HEPATICE,
FAȚĂ DE MĂSURILE STANDARD DE ÎNGRIJIRE^{*1,2}

ESSENTIALE® SUSȚINE REGENERAREA FICATULUI CELULĂ CU CELULĂ



ESSENTIALE® îmbunătățește calitatea vieții (CLDQ-MASLD/MASH) prin reducerea scorului de oboseală.⁴



ESSENTIALE® crește nivelul de energie al pacienților prin reducerea oboselii.⁴



Reducere semnificativă a steatozei cu ESSENTIALE® din datele de după 3 și 6 luni.^{1,2}



ESSENTIALE® susține controlul glicemic la pacienții cu MASLD/MAFLD.¹



Fosfolipide esențiale
cu o concentrație ridicată
de **76%** fosfatidilcolină și
o absorbție de
peste **90%**¹⁻³

Acest studiu a inclus 193 de pacienți cu vârste cuprinse între 18-70 ani, cu MASLD, steatoză (S1-S3) și fibroză (F1-F3). Pacienții au fost randomizați pentru a primi fie fosfolipide esențiale (FLE) în doză de 1800 mg/zi (N = 97), fie placebo (N = 96) timp de 6 luni, în combinație cu tratamentul standard (TS). Vizitele de urmărire au fost efectuate în lunile 3, 6 și 9.

*Studiul clinic a avut loc în UE.

Doze și mod de administrare: Essentiale MAX: Copii cu vârsta peste 12 ani (aproximativ 43 kg), adolescenți și adulți - Doza zilnică: 1 capsulă de 3 ori pe zi; doza zilnică: 1800 mg fosfolipide din semințe de soia.

CLDQ: Chestionar pentru boala hepatică cronică; MAFLD: Boala hepatică grasă asociată cu disfuncție metabolică; MASH: Steatohepatită asociată cu disfuncție metabolică; MASLD: Boală hepatică steatotică asociată cu disfuncția metabolică.

RCP: https://www.anm.ro/_RCP/RCP_15811_31.01.25.pdf

REFERINȚE: 1. Stefan N, et al. Poster presented at: EASL SLD Summit; January 23 - 25, 2025; Estoril, Portugal. (Poster ID: PO7-01); 2. Stefan N, et al. Poster presented at: AASLD; November 15 - 19, 2024; San Diego, CA, USA. (Poster ID: 5037); 3. Gundermann KJ, et al. Pharmacol Rep. 2011;63:643-659; 4. Younossi ZM, et al. Liver Int. 2017;37(8):1209-1218; 5. Stefan N, et al. Trials. 2024;25(1):374.

Opella.

Gara Herăstrău 4C, Clădirea B,
Etaj 8, București, România

Tel.: (+40) 21 317 31 36

Lagosa[®]
silimarină 150mg

Ficatul e tăcut
atunci când suferă

Obiceiurile nesănătoase pot duce
la un efect toxic asupra ficatului.

**Ficatul nu doare
când îl doare**
Ai grijă de el cu



detoxifiant

regenerator

antioxidant

protector


Acest medicament conține silimarină și se poate elibera fără prescripție medicală. Se recomandă citirea cu atenție a prospectului sau a informațiilor de pe ambalaj. Dacă apar manifestări neplăcute, adresați-vă medicului sau farmacistului. Medicamentele expirate și/sau neutilizate se consideră deșeuri periculoase. Viza de publicitate nr. 6578/05.01.2025

wörwag
PHARMA

Mounjaro: singurul agonist al receptorilor GIP și GLP-1 aprobat pentru controlul greutateii

ÎN SURMOUNT-5 Mounjaro[®] a demonstrat reducere superioară a greutateii comparativ cu semaglutida²

La săptămâna 72, participanții tratați cu Mounjaro DMT (10 mg sau 15 mg) au înregistrat o reducere medie superioară a greutateii de **-21,6%^a** comparativ cu **-15,4%^a** la cei tratați cu semaglutidă în doză maximă tolerată (1,7 mg sau 2,4 mg)^{2,3,4}



^aDatele sunt prezentate ca medie a celor mai mici pătrate cu un interval de încredere de 95% sau ca procente. Doar datele la săptămâna 72 au fost prespecificate și verificate pentru multiplicitate.²

Studiul SURMOUNT-5 a comparat tirzepatida DMT (10 mg sau 15 mg) și semaglutida DTM (1,7 mg sau 2,4 mg), doza maximă aprobată de semaglutidă pentru controlul greutateii la momentul inițierii studiului. Semaglutida 7,2 mg nu a fost evaluată în acest studiu. DMT=doza maximă tolerată

▼Acest medicament face obiectul unei monitorizări suplimentare. Acest lucru vă permite identificarea rapidă de noi informații referitoare la siguranță. Profesioniștii din domeniul sănătății sunt rugați să raporteze orice reacții adverse suspectate. Raportați o reacție adversă către: Lilly: phv_centre_see@lilly.com; ANMDM: adr@anm.ro

*SURMOUNT-5 a fost un studiu de fază 3b, cu durată de 72 de săptămâni, multicentric, randomizat, cu brațe paralele, deschis, controlat cu comparator, care a evaluat eficacitatea și siguranța Mounjaro 15 mg sau a dozei maxime tolerate (10 mg sau 15 mg) comparativ cu Semaglutida 2,4 mg sau doza maximă tolerată (1,7 mg sau 2,4 mg) la adulți cu obezitate (IMC ≥ 30 kg/m²) sau supraponderali (IMC ≥ 27 kg/m²) cu cel puțin o complicație asociată obezității (de exemplu, hipertensiune, dislipemie), excluzând diabetul.² Limitările unui studiu deschis pot fi legate de un posibil bias în evaluarea rezultatelor, eficacității și/sau siguranței, iar analiza nu a fost comparată cu un grup de control placebo.² ³Estimarea eficacității, populația mITT, analiză MMRM.²

1. Mounjaro Rezumatul Caracteristicilor Produsului, ultima variantă disponibilă; 2. Aronne LJ, et al. N Engl J Med. Published online ahead of print, May 12, 2025.

Acest material este destinat profesioniștilor din domeniul sănătății.

PP-TR-RO-0636



O DATĂ PE SĂPTĂMÂNĂ

wegovy® ▼

semaglutidă injectabilă

Împreună pentru

O VIAȚĂ TRĂITĂ MAI UȘOR

cu Wegovy®

Doar Wegovy® asigură scădere în greutate de calitate și beneficii cardiovasculare dovedite persoanelor cu obezitate¹⁻⁵

-21%

scădere în greutate medie¹



Portretizare pacient

1. Wharton S, Freitas P, Hjelmæsæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. *Lancet Diabetes Endocrinol.* 2025;S2213-8587(25)00226-8. Online ahead of print. 2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med.* 2023;389(24):2221-2232. 3. Rezumatul Caracteristicilor Produsului Wegovy 4. Wilson L, Zhao Z, Divino V, Bassan M, Harthaigh BO, Ozer K. Semaglutide is associated with a lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice. Results from the STEER study. Presented at: ESC Congress 2025; August 29- September 1, 2025; Madrid, Spain. 5. Hjelmæsæth J, Bhat S, Garvey WT, et al. Effect of semaglutide on body composition and proximal muscle strength: the STEP UP trial. Presented at: The 61st European Association for the Study of Diabetes (EASD) Annual Meeting; September 15-19, 2025; Vienna, Austria.

Pentru mai multe detalii privind instrucțiunile de utilizare, vă rugăm să consultați Rezumatul Caracteristicilor Produsului Wegovy®. Medicament eliberat pe bază de prescripție medicală – PRF. Data primei autorizări: 06/01/2022

Acest material promoțional este destinat profesioniștilor din domeniul sănătății.

▼ Acest medicament face obiectul unei monitorizări suplimentare. Acest lucru va permite identificarea rapidă de noi informații referitoare la siguranță. Profesioniștii din domeniul sănătății sunt rugați să raporteze orice reacție adversă suspectată la Novo Nordisk Farma SRL la adresa de e-mail: safetyro@novonordisk.com sau la Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România, Str. Aviator Sănătescu nr. 48, sector 1, București 011478-RO, e-mail: adr@anm.ro, Website: www.anm.ro

Novo Nordisk România

Strada Buzești, nr. 82-94, etaj 9, sector 1,
București, cod poștal 011017, România
Tel: +4021 312 36 74, www.novonordisk.com
Martie 2026, RO26SEMO00146



HEPCLUDEX® - CALEA SPRE VIITOR ÎN TRATAMENTUL HEPATITEI DELTA



HEPCLUDEX®
bulevirtidă 2mg

Rezumatul Caracteristicilor
Produsului Hepcludex® este
disponibil scanând codul QR:



▼ Acest medicament face obiectul unei monitorizări suplimentare. Acest lucru va permite identificarea rapidă de noi informații referitoare la siguranță. Acest material promoțional este adresat profesioniștilor din domeniul sănătății. Consultați Rezumatul Caracteristicilor Produsului pentru informații complete de prescriere. Informații detaliate privind acest medicament, sunt disponibile pe site-ul Agenției Europene pentru Medicamente <http://www.ema.europa.eu>. Medicament eliberat pe baza de prescripție medicală restrictivă PR. Profesioniștii din domeniul sănătății sunt rugați să raporteze orice reacție adversă suspectată, la Gilead Sciences (GSR) S.R.L., la adresa de email: Safety_FC@gilead.com sau la Agenția Națională a Medicamentului și a Dispozitivelor Medicale: Str. Aviator Sănătescu nr. 48, sector 1, București 011478-RO, Tel: + 4 0757 117 259, Fax: +4 0213 163 497, email.adr@anm.ro

GILEAD SCIENCES ROMÂNIA GSR SRL
Calea Griviței nr. 82-98, Clădirea The Mark,
Corp Podium, birou nr. E1.40, et. 1, sector 1, București
RO-HPX-0029

 **GILEAD**

EXPOZANȚI

PARTENERI MEDIA

Journal de
Sănătate
GASTROENTEROLOGIE
www.jurmed.ro

**MEDICAL
MARKET**

**VIATA
MEDICALA**